<SEC-DOCUMENT>0001193125-22-242028.txt : 20220909
<SEC-HEADER>0001193125-22-242028.hdr.sgml : 20220909
<ACCEPTANCE-DATETIME>20220909164304
ACCESSION NUMBER:		0001193125-22-242028
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220909
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220909
DATE AS OF CHANGE:		20220909

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34375
		FILM NUMBER:		221236620

	BUSINESS ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756
		BUSINESS PHONE:		737.255.7194

	MAIL ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTORI THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d359404d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pstv="http://www.plustherapeutics.com/20220909" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName" name="dei:SecurityExchangeName" contextRef="duration_2022-09-09_to_2022-09-09">NASDAQ</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-09-09_to_2022-09-09">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-09-09_to_2022-09-09">0001095981</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="pstv-20220909.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-09-09_to_2022-09-09"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-09</xbrli:startDate> <xbrli:endDate>2022-09-09</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-09-09_to_2022-09-09">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Current Report</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-09-09_to_2022-09-09" format="ixt:datemonthdayyearen">September&#160;9, 2022</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-09-09_to_2022-09-09">PLUS THERAPEUTICS, INC.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-09-09_to_2022-09-09" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-09-09_to_2022-09-09">001-34375</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-09-09_to_2022-09-09">33-0827593</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-09-09_to_2022-09-09">4200 Marathon Blvd.</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2022-09-09_to_2022-09-09">Suite 200</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-09-09_to_2022-09-09">Austin</ix:nonNumeric>,</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-09-09_to_2022-09-09" format="ixt-sec:stateprovnameen">Texas</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-09-09_to_2022-09-09">78756</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, with zip code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-09-09_to_2022-09-09">(737)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-09-09_to_2022-09-09">255-7194</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-09-09_to_2022-09-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-09-09_to_2022-09-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-09-09_to_2022-09-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-09-09_to_2022-09-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-09-09_to_2022-09-09">Common Stock, par value $0.001</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-09-09_to_2022-09-09">PSTV</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName">The Nasdaq Capital Market</span> </span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#160;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-09-09_to_2022-09-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;9, 2022, Plus Therapeutics, Inc. (the &#8220;Company&#8221;) entered into an Equity Distribution Agreement (the &#8220;Distribution Agreement&#8221;) with Canaccord Genuity LLC (the &#8220;Agent&#8221;), pursuant to which the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $5,000,000 (the &#8220;Shares&#8221;), depending on market demand, with the Agent acting as an agent for sales. Sales of the Shares may be made by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), including, without limitation, sales made directly on or through the NASDAQ Capital Market. The Agent will use its commercially reasonable efforts to sell the Shares requested by the Company to be sold on its behalf, consistent with the Agent&#8217;s normal trading and sales practices, under the terms and subject to the conditions set forth in the Distribution Agreement. The Company has no obligation to sell any of the Shares. The Company may instruct the Agent not to sell the Shares if the sales cannot be effected at or above the price designated by the Company from time to time and the Company may at any time suspend sales pursuant to the Distribution Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will pay the Agent a commission of up to 3.0% of the gross proceeds from the sale of Shares by the Agent under the Distribution Agreement. The Company has also agreed to reimburse the Agent for its reasonable <span style="white-space:nowrap"><span style="white-space:nowrap">documented&#160;out-of-pocket&#160;expenses,</span></span> including fees and disbursements of its counsel, in the amount of $50,000. In addition, the Company has agreed to provide customary indemnification rights to the Agent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Offering will terminate upon the earlier of (1)&#160;the issuance and sale of all shares of the Company&#8217;s common stock subject to the Distribution Agreement, or (2)&#160;the termination of the Distribution Agreement as permitted therein, including by either party at any time without liability of any party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any sales of Shares under the Distribution Agreement will be made pursuant to the Company&#8217;s Registration Statement on <span style="white-space:nowrap">Form&#160;S-3</span> <span style="white-space:nowrap">(File&#160;No.&#160;333-249410),&#160;including</span> the related prospectus, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on October&#160;9, 2020 and declared effective on October&#160;19, 2020, as supplemented by the prospectus supplement dated September&#160;9, 2022, and any applicable additional prospectus supplements related to the Offering that form a part of the Registration Statement. The aggregate market value of Shares eligible for sale in the Offering and under the Distribution Agreement will be subject to the limitations of General Instruction I.B.6 of <span style="white-space:nowrap">Form&#160;S-3,&#160;to</span> the extent required under such instruction. The Company intends to use the net proceeds from this offering for general corporate purposes and for working capital. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Distribution Agreement does not purport to be complete and is qualified in its entirety by reference to the Distribution Agreement, which is filed as Exhibit 1.1 to this report and is incorporated herein by reference. A copy of the legal opinion of Hogan Lovells US LLP regarding the legality of the issuance and sale of the Shares is filed as Exhibit 5.1 to this report and is incorporated by reference herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;does</span> not constitute an offer to sell or the solicitation of an offer to buy any Shares, nor shall there be any offer, solicitation or sale of any Shares, in any jurisdiction in which it is unlawful to make the offer, solicitation or sale. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d359404dex11.htm">Distribution Agreement, dated September&#160;9, 2022, by and among Plus Therapeutics, Inc. and Canaccord Genuity LLC </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d359404dex51.htm">Opinion of Hogan Lovells LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d359404dex51.htm">Consent of Hogan Lovells LLP (contained in Exhibit&#160;5.1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: September&#160;9, 2022 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:92%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">PLUS THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Sims</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Andrew Sims</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Chief Financial Officer</td></tr>
</table></div>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d359404dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLUS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EQUITY DISTRIBUTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">September&nbsp;9, 2022 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CANACCORD GENUITY LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">99 High Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02110 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As further set forth in
this agreement (this <B><I>&#147;</I></B><B><I>Agreement</I></B><B><I>&#148;</I></B>), Plus Therapeutics, Inc., a Delaware corporation (the <B><I>&#147;Company&#148;</I></B>), proposes to issue and sell from time to time through Canaccord Genuity
LLC (the <B><I>&#147;</I></B><B><I>Agent</I></B><B><I>&#148;</I></B>), as sales agent, the Company&#146;s common stock, $0.001 par value per share (the <B><I>&#147;Common Shares&#148;</I></B>) (such Common Shares to be sold pursuant to this
Agreement, the <B><I>&#147;Shares&#148;</I></B>), having an aggregate offering price of up to $5,000,000, on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the
limitation set forth in Section&nbsp;2 of this Agreement on the number of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and the Agent shall have no obligation in connection with such compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreement with the Agent with respect to the sale of the Shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>1.</I></B><B><I> Representations and Warranties of the Company</I></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Company represents and warrants to, and agrees with, the Agent that as of the date of this Agreement, each
Representation Date, each date on which a Placement Notice (as defined in Section&nbsp;2(a)(i) below) is given, and any date on which Shares are sold hereunder as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>Registration Statement and Prospectus</I>. The Company has filed, in accordance with the
provisions of the Securities Act of 1933, as amended, and the rules and regulations thereunder (collectively, the <B><I>&#147;Securities Act&#148;</I></B>), with the Securities and Exchange Commission (the <B><I>&#147;Commission&#148;</I></B>) a
registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-249410),</FONT> including a base prospectus, relating to certain securities, including the Common Shares, to be issued
from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder
(collectively, the <B><I>&#147;Exchange Act&#148;</I></B>). The Company has prepared a prospectus supplement to the base prospectus included as part of such registration statement specifically relating to a portion of the Shares (the
<B><I>&#147;Prospectus Supplement&#148;</I></B>). The Company has furnished to the Agent, for use by Agent, copies of the prospectus included as part of such registration statement, as supplemented by the Prospectus Supplement, relating to the
Shares. Except where the context otherwise requires, such registration statement, as amended when it became effective, including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a
Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such registration statement pursuant to Rule 430B or 462(b) of the Securities Act, is herein called the
<B><I>&#147;Registration Statement.&#148;</I></B> The base prospectus, including all documents incorporated therein by reference, included in the Registration Statement, as it may be supplemented by the Prospectus Supplement, in the form in which
such prospectus and/or Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act, together with any &#147;issuer free writing prospectus,&#148; as defined in Rule 433 of
the Securities Act regulations (<B><I>&#147;Rule 433&#148;</I></B>), relating to the Shares, if any, that (i)&nbsp;is required to be filed with the Commission by the Company or (ii)&nbsp;is exempt from filing pursuant to Rule 433(d)(5)(i), in each
case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company&#146;s records pursuant to Rule 433(g), is herein called the <B><I>&#147;Prospectus.&#148;</I></B> Any reference
herein to the Registration Statement, the Prospectus or any amendment or supplement thereto shall be deemed to refer to and include the documents incorporated by reference therein, and any reference herein to the terms &#147;amend,&#148;
&#147;amendment&#148; or &#147;supplement&#148; with respect to the Registration Statement or the Prospectus shall be deemed to refer to and include the filing after the execution hereof of any document with the Commission deemed to be incorporated
by reference therein. For purposes of this Agreement, all references to the Registration Statement, the Prospectus or to any amendment or supplement thereto shall be deemed to include any copy filed with the Commission pursuant the Electronic Data
Gathering Analysis and Retrieval System (&#147;<B><I>EDGAR&#148;</I></B>). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) &nbsp;&nbsp;&nbsp;&nbsp;<I>Continuing Effectiveness of Registration
Statement</I>. The Registration Statement and any Rule&nbsp;462(b) Registration Statement have been declared effective by the Commission under the Securities Act. The Company has complied, to the Commission&#146;s satisfaction, with all requests of
the Commission for additional or supplemental information. No stop order suspending the effectiveness of the Registration Statement or any Rule&nbsp;462(b) Registration Statement is in effect and no proceedings for such purpose have been instituted
or are pending or, to the knowledge of the Company, contemplated or threatened by the Commission. The Company meets the requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act. The sale of the Shares
hereunder meets the requirements of General Instruction I.B.6. of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> The aggregate market value of securities sold by or on behalf of the Company pursuant to General Instruction I.B.6. of Form <FONT
STYLE="white-space:nowrap">S-3</FONT> during the 12 month period immediately prior to, and including, the sale of those Shares described in the Prospectus Supplement pursuant to this Agreement is no more than
<FONT STYLE="white-space:nowrap">one-third</FONT> of the aggregate market value of the voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common equity held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of the Company, as
determined pursuant to General Instruction I.B.6. of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)
&nbsp;&nbsp;&nbsp;&nbsp;<I>No Material Misstatements or Omissions</I>. The Prospectus when filed complied, and as amended or supplemented, if applicable, will comply in all material respects with the Securities Act. Each of the Registration
Statement, any Rule&nbsp;462(b) Registration Statement, the Prospectus and any post-effective amendments or supplements thereto, at the time it became effective or its date, as applicable, and as of each Settlement Date (as defined in
Section&nbsp;2(a)(vii) below), complied in all material respects with the Securities Act, and as of each effective date and each Settlement Date, did not and will not contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein not misleading. The Prospectus, as amended or supplemented, as of its date, did not and, as of each of the Settlement Date, will not contain any untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The representations and warranties set forth in the two immediately preceding
sentences do not apply to statements in or omissions from the Registration Statement, any Rule&nbsp;462(b) Registration Statement, or any post-effective amendment thereto, or the Prospectus, or any amendments or supplements thereto, made in reliance
upon and in conformity with information relating to the Agent furnished to the Company in writing by the Agent expressly for use therein. There are no contracts or other documents required to be described in the Prospectus or to be filed as exhibits
to the Registration Statement which have not been described or filed as required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;<I>Eligible Issuer</I>. The Company is not an
&#147;ineligible issuer&#148; (as defined in Rule 405 under the Securities Act) as of the eligibility determination date for purposes of Rules 164 and 433 under the Securities Act with respect to the offering of the Shares contemplated by the
Registration Statement; the parties hereto agree and understand that the content of any and all &#147;road shows&#148; (as defined in Rule 433 under the Securities Act) related to the offering of the Shares contemplated hereby is solely the property
of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) &nbsp;&nbsp;&nbsp;&nbsp;<I>Financial Statements</I>. The historical financial statements (including
the related notes and supporting schedules) to be included or incorporated by reference, in the Registration Statement, and the Prospectus comply as to form in all material respects with the requirements of Regulation
<FONT STYLE="white-space:nowrap">S-X</FONT> under the Securities Act (<B><I>&#147;Regulation <FONT STYLE="white-space:nowrap">S-X&#148;</FONT></I></B>) and present fairly in all material respects, the financial condition, results of operations and
cash flows of the entities purported to be shown thereby at the dates and for the periods indicated and have been prepared in conformity with generally accepted accounting principles in the United States applied on a consistent basis throughout the
periods involved. There are no financial statements (historical or pro forma) that are required to be included in the Registration Statement or the Prospectus that are not so included as required. The interactive data in eXtensible Business
Reporting Language (<B><I>&#147;XBRL&#148;</I></B>) included or incorporated by reference in the Registration Statement and the Prospectus fairly present the information called for in all material respects and have been prepared in accordance with
the Commission&#146;s rules and guidelines applicable thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) &nbsp;&nbsp;&nbsp;&nbsp;<I>No <FONT
STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Transactions</I>. There are no transactions, arrangements and other relationships between and/or among the Company, and/or, to the knowledge of the Company, any of its affiliates and any
unconsolidated entity, including, but not limited to, any structural finance, special purpose or limited purpose entity (each, an &#147;<B><I><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Transaction&#148;</I></B>) that could reasonably
be expected to affect materially the Company&#146;s liquidity or the availability of or requirements for its capital resources, including those Off Balance Sheet Transactions described in the Commission&#146;s Statement about Management&#146;s
Discussion and Analysis of Financial Conditions and Results of Operations (Release Nos. <FONT STYLE="white-space:nowrap">33-8056;</FONT> <FONT STYLE="white-space:nowrap">34-45321;</FONT> <FONT STYLE="white-space:nowrap">FR-61),</FONT> and are
required to be described in the Prospectus, which have not been described as required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;<I>Auditor Independence.</I> BDO USA, LLP, who
have certified certain financial statements of the Company and its consolidated subsidiaries (the <B><I>&#147;Subsidiaries&#148;</I></B>), whose report appears in the Registration Statement and the Prospectus, are independent public accountants as
required by the Securities Act and the Public Accounting Oversight Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Material
Adverse Effect</I>. The Company and each of its Subsidiaries (a complete list of the Subsidiaries is included on <U>Schedule 4</U> hereto) has been duly organized, validly existing as a corporation and in good standing under the laws of their
respective jurisdictions of organization. The Company and each of its Subsidiaries are, and will be, duly licensed or qualified as a foreign corporation for transaction of business and in good standing under the laws of each other jurisdiction in
which their respective ownership or lease of property or the conduct of their respective businesses requires such license or qualification, and have all corporate power and authority necessary to own or hold their respective properties and to
conduct their respective businesses as described in the Registration Statement and the Prospectus, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a
material adverse effect or would reasonably be expected to have a material adverse effect on or affecting the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders&#146; equity or results of
operations of the Company and the Subsidiaries taken as a whole, or prevent or materially interfere with consummation of the transactions contemplated hereby (a <B><I>&#147;Material Adverse Effect&#148;</I></B>). The Company does not own or control,
directly or indirectly, any corporation, association or other entity other than the Subsidiaries listed on <U>Schedule 4</U> hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) &nbsp;&nbsp;&nbsp;&nbsp;<I>Capitalization</I>. The Company has an authorized capitalization as set forth in each of the
Registration Statement and the Prospectus, and all of the issued and outstanding shares of the Company have been duly authorized and validly issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> conform in all material
respects to the description thereof contained in the Registration Statement and the Prospectus and were not issued in violation of any preemptive right, resale right, right of first refusal or similar right. All of the Company&#146;s options,
warrants and other rights to purchase or exchange any securities for shares of the Company&#146;s capital stock have been duly authorized and validly issued, and conform in all material respects to the description thereof contained in the
Registration Statement and the Prospectus. All of the issued shares of capital stock or other ownership interest of each Subsidiary of the Company have been duly authorized and validly issued, are fully paid and
<FONT STYLE="white-space:nowrap">non-assessable</FONT> and are owned directly or indirectly by the Company, free and clear of all liens, encumbrances, equities or claims, except for such liens, encumbrances, equities or claims as would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) &nbsp;&nbsp;&nbsp;&nbsp;<I>Due Authorization, Valid Issuance and <FONT
STYLE="white-space:nowrap">Non-Assessiblity</FONT> of Shares</I>. The Shares to be issued and sold by the Company to the Agent hereunder have been duly authorized, and upon payment and delivery in accordance with this Agreement, will be validly
issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> will conform in all material respects to the description thereof contained in the Registration Statement and the Prospectus, will be issued in compliance with federal and
state securities laws and will be free of statutory and contractual preemptive rights, rights of first refusal and similar rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi) &nbsp;&nbsp;&nbsp;&nbsp;<I>Authority to Enter into this Agreement</I>. The Company has all requisite corporate power and
authority to execute, deliver and perform its obligations under this Agreement. This Agreement has been duly and validly authorized, executed and delivered by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xii) &nbsp;&nbsp;&nbsp;&nbsp;<I><FONT STYLE="white-space:nowrap">Non-Contravention</FONT></I>. The issue and sale of the
Shares, the execution, delivery and performance of this Agreement by the Company, the consummation of the transactions contemplated hereby and the application of the proceeds from the sale of the Shares as described under &#147;Use of Proceeds&#148;
in the Registration Statement and the Prospectus will not (i)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions of, impose any lien, charge or encumbrance upon any property or assets of the Company and its
Subsidiaries, or constitute a default under, any indenture, mortgage, deed of trust, loan agreement, license, lease or other agreement or instrument to which the Company or any of its Subsidiaries is a party or by which the Company or any of its
Subsidiaries is bound or to which any of the property or assets of the Company or any of its Subsidiaries is subject; (ii)&nbsp;result in any violation of the provisions of the articles of association, charter or
<FONT STYLE="white-space:nowrap">by-laws</FONT> (or similar organizational documents) of the Company or any of its Subsidiaries; or (iii)&nbsp;result in any violation of any statute or any judgment, order, decree, rule or regulation of any court or
governmental agency or body having jurisdiction over the Company or any of its Subsidiaries or any of their properties or assets, except, with respect to clauses (i)&nbsp;and (iii), for such conflicts, breaches, violations, liens, charges,
encumbrances or defaults that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiii) &nbsp;&nbsp;&nbsp;&nbsp;<I>No Consent or Approval Required</I>. No consent, approval, authorization or order of, or
filing, registration or qualification with, any court or governmental agency or body having jurisdiction over the Company or any of its Subsidiaries or any of their properties or assets is required for the issue and sale of the Shares, the
execution, delivery and performance of this Agreement by the Company, the consummation of the transactions contemplated hereby, the application of the proceeds from the sale of the Shares as described under &#147;Use of Proceeds&#148; in the
Registration Statement and the Prospectus, except for (i)&nbsp;the registration of the Shares under the Securities Act; (ii)&nbsp;such consents, approvals, authorizations, orders, filings, registrations or qualifications as may be required under the
Exchange Act, and applicable state or foreign securities laws and/or the bylaws and rules of the Financial Industry Regulatory Authority (the <B><I>&#147;FINRA&#148;</I></B>) in connection with the sale of the Shares by the Agent; and (iii)&nbsp;the
inclusion of the Shares on the Nasdaq Capital Market (the <B><I>&#147;Exchange&#148;</I></B>). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiv) &nbsp;&nbsp;&nbsp;&nbsp;<I>Internal Accounting Controls</I>. The
Company and each of its Subsidiaries maintain internal accounting controls designed to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles in the United States, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s
general or specific authorization, (ii)&nbsp;transactions are recorded as necessary to permit preparation of the Company&#146;s financial statements in conformity with generally accepted accounting principles in the United States and to maintain
accountability for its assets, (iii)&nbsp;access to the Company&#146;s assets is permitted only in accordance with management&#146;s general or specific authorization, (iv)&nbsp;the recorded accountability for the Company&#146;s assets is compared
with existing assets at reasonable intervals and appropriate action is taken with respect to any differences, and (v)&nbsp;the interactive data in XBRL included or incorporated by reference in the Registration Statement and the Prospectus fairly
present the information called for in all material respects and are prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. Except as disclosed in the Registration Statement or the Prospectus, as of the date of the
most recent balance sheet of the Company and its consolidated Subsidiaries audited by BDO USA, LLP, there were no material weaknesses in the Company&#146;s internal controls. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xv)&nbsp;&nbsp;&nbsp;&nbsp;<I>Disclosure Controls</I>. The Company and each of its Subsidiaries maintain disclosure controls
and procedures (as such term is defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> under the Exchange Act) designed to ensure that the information required to be disclosed by the Company and its Subsidiaries in the reports they file
or submit under the Exchange Act is accumulated and communicated to management of the Company and its Subsidiaries, including their respective principal executive officers and principal financial officers, as appropriate, to allow timely decisions
regarding required disclosure to be made, and such disclosure controls and procedures are effective in all material respects to perform the functions for which they were established. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvi) &nbsp;&nbsp;&nbsp;&nbsp; <I>Critical Accounting Policies</I>. The section entitled &#147;Critical Accounting
Policies&#148; incorporated by reference in the Registration Statement and the Prospectus accurately describes in all material respects (i)&nbsp;the accounting policies that the Company believes are the most important in the portrayal of the
Company&#146;s financial condition and results of operations and that require management&#146;s most difficult, subjective or complex judgments (&#147;<B><I>Critical Accounting Policies</I></B>&#148;); (ii) the judgments and uncertainties affecting
the application of Critical Accounting Policies; and (iii)&nbsp;the likelihood that materially different amounts would be reported under different conditions or using different assumptions, and an explanation thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvii) &nbsp;&nbsp;&nbsp;&nbsp;<I>Sarbanes-Oxley Compliance</I>. There is and has been no failure on the part of the Company
or, to the knowledge of the Company, any of the Company&#146;s directors or officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith that
are applicable to the Company or its directors or officers in their capacities as directors or officers of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xviii) &nbsp;&nbsp;&nbsp;&nbsp;<I>Exceptions</I>. Except as would not, in
the aggregate, reasonably be expected to have a Material Adverse Effect, since the date of the latest audited financial statements included in the Registration Statement and the Prospectus, and, except as disclosed in the Registration Statement and
the Prospectus, neither the Company nor any of its Subsidiaries has (i)&nbsp;sustained any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court
or governmental action, order or decree, (ii)&nbsp;issued or granted any securities (other than pursuant to employee benefit plans, qualified stock option plans or other equity compensation plans or arrangements existing on the date hereof and
disclosed in the Registration Statement and the Prospectus (the <B><I>&#147;Specified Equity Plans&#148;</I></B>)), (iii) incurred any material liability or obligation, direct or contingent, other than liabilities and obligations that were incurred
in the ordinary course of business, (iv)&nbsp;entered into any material transaction not in the ordinary course of business, or (v)&nbsp;declared or paid any dividend on its share capital; and since such date, except as disclosed in the Registration
Statement and the Prospectus, there has not been any change in the share capital (other than in connection with issuances pursuant to the Specified Equity Plans), long-term debt, net current assets or short-term debt of the Company or any of its
Subsidiaries or any adverse change, or any development involving a prospective adverse change, in or affecting the condition (financial or otherwise), results of operations, shareholders&#146; equity, properties, management, business or prospects of
the Company and its Subsidiaries taken as a whole. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xix)&nbsp;&nbsp;&nbsp;&nbsp;<I>Valid Title</I>. The Company and each
of its Subsidiaries have good and marketable title in fee simple to all real property and good and marketable title to all personal property owned by them, that are material to the business of the Company, in each case free and clear of all liens,
encumbrances and defects, except such liens, encumbrances and defects as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and its
Subsidiaries. All assets held under lease by the Company and its Subsidiaries, that are material to the business of the Company, are held by them under valid, subsisting and enforceable leases, with such exceptions as do not materially interfere
with the use made and proposed to be made of such assets by the Company and its Subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xx)&nbsp;&nbsp;&nbsp;&nbsp;
<I>Intellectual Property</I>. The Company and each of its Subsidiaries owns, possesses or has valid and enforceable licenses to use, or can acquire on reasonable terms, all Intellectual Property (as defined below) necessary for the conduct of the
Company&#146;s and it Subsidiaries&#146; business as now conducted or as described in the Registration Statement and the Prospectus to be conducted, except as such failure to own, possess, or acquire such rights would not reasonably be expected to,
individually or in the aggregate, result in a Material Adverse Effect. Furthermore, (A)&nbsp;to the knowledge of the Company, there is no infringement, misappropriation or violation by third parties of any such Intellectual Property, the effect of
which would have a Material Adverse Effect; (B)&nbsp;there is no pending or, to the knowledge of the Company, threatened, action, suit, proceeding or claim by others challenging the Company&#146;s or any of its Subsidiaries&#146; rights in or to any
such Intellectual Property, the effect of which would have a Material Adverse Effect; (C)&nbsp;the Intellectual Property owned by the Company and its Subsidiaries, and to the knowledge of the Company, the Intellectual Property licensed to the
Company and its Subsidiaries, has not been adjudged invalid or unenforceable, in whole or in part, and there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the validity or scope
of any such Intellectual Property, the effect of which would have a Material Adverse Effect; (D)&nbsp;there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others that the Company or any of its
Subsidiaries infringes, misappropriates or otherwise violates any Intellectual Property or other proprietary rights of others, and neither the Company or any of its Subsidiaries has received any written notice of such claim, the effect of which
would have a Material Adverse Effect; and (E)&nbsp;to the Company&#146;s knowledge, no employee of the Company or any of its Subsidiaries is in or has ever been in violation of any term of any employment contract, patent disclosure agreement,
invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement or any restrictive covenant to or with a former employer
where the basis of such violation relates to such employee&#146;s employment with the Company or any of its Subsidiaries or actions undertaken by the employee while employed with the Company or any of its Subsidiaries, the effect of which would have
a Material Adverse Effect. &#147;<B><I>Intellectual Property</I></B>&#148; shall mean all patents, patent applications, trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets,
domain names, technology, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxi)&nbsp;&nbsp;&nbsp;&nbsp; <I>Consents and Permits</I>. Except as set
forth in the Registration Statement and the Prospectus, the Company and each of its Subsidiaries have such permits, licenses, patents, franchises, certificates of need and other approvals consents and other authorizations (the &#147;<B><I>Regulatory
Permits</I></B>&#148;) issued by the appropriate domestic or foreign regional, federal, state, or local regulatory agencies or bodies necessary to conduct the business of the Company, including, without limitation, any Regulatory Permits required by
the U.S. Food and Drug Administration (the &#147;<B><I>FDA</I></B>&#148;) or any other authorizations issued by domestic or foreign regional, federal, state, or local agencies or bodies engaged in the regulation of products such as those being
developed by the Company and its Subsidiaries, except for any of the foregoing that would not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect; the Company (i)&nbsp;is in compliance in all material respects
with the requirements of the Regulatory Permits, and (ii)&nbsp;all of the Regulatory Permits are valid and in full force and effect, in each case, except for any of the foregoing that would not reasonably be expected to, individually or in the
aggregate, have a Material Adverse Effect; the Company has not received any written notice of proceedings relating to the revocation, termination, modification or impairment of rights of any of the Regulatory Permits that, individually or in the
aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to result in a Material Adverse Effect; the Company has not failed to submit to the FDA any applications or other filings necessary to conduct the
business of the Company, any such filings that were required to be made were in material compliance with applicable laws when filed, and no material deficiencies have been asserted by the FDA with respect to any such filings or submissions that were
made. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxii)&nbsp;&nbsp;&nbsp;&nbsp;<I>Compliance with Applicable Laws and
Regulations</I>. Except as would not reasonably be expected to have a Material Adverse Effect or as described in the Registration Statement and Prospectus, as applicable, the Company and each of its Subsidiaries and, to the Company&#146;s knowledge,
the directors, officers, employees, and agents (while acting in such capacity) of the Company and each of its Subsidiaries are, and at all times have been, in compliance with, all health care laws and regulations applicable to the Company or its
Subsidiaries, including all such health care laws and regulations pertaining to development and testing of health care products or medical devices, fraud and abuse, kickbacks, recordkeeping, documentation requirements, the hiring of employees (to
the extent governed by health care laws), quality, safety, privacy, security, licensure, ownership, manufacturing, packaging, labeling, processing, use, distribution, storage, import, export, advertising, promotion, marketing or disposal of health
care products or medical devices (collectively, the <B><I>&#147;Applicable Laws&#148;</I></B>); (ii) have not received any notice from any court or arbitrator or governmental or regulatory authority or third party alleging or asserting noncompliance
with any Applicable Laws or any licenses, exemptions, certificates, approvals, clearances, authorizations, permits, registrations and supplements or amendments thereto required by any such Applicable Laws (<B><I>&#147;Authorizations&#148;</I></B>);
(iii) possess all Authorizations and such Authorizations are valid and in full force and effect and are not in violation of any term of any such Authorizations; (iv)&nbsp;have not received written notice of any claim, action, suit, proceeding,
hearing, enforcement, investigation arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Applicable Laws or
Authorizations nor is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened; (v)&nbsp;have received any written notice that any court or arbitrator or governmental or regulatory
authority has taken, is taking or intends to take, action to limit, suspend, materially modify or revoke any Authorizations nor is any such limitation, suspension, modification or revocation threatened; (vi)&nbsp;have filed, obtained, maintained or
submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed (or were corrected or supplemented by a subsequent submission); and (vii)&nbsp;are not a party to any corporate integrity
agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><I>(xxiii) No Safety Notices. </I>Except as would not reasonably be expected to have a Material Adverse Effect or as disclosed
in the Registration Statement and the Prospectus, there have been no recalls, field notifications, corrections or removals, market withdrawals or replacements, warnings, &#147;dear doctor&#148; letters, investigator notices, safety alerts, safety
communications or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the products of the Company or any of its Subsidiaries (&#147;<B><I>Safety Notices</I></B>&#148;). To the Company&#146;s knowledge,
there are no facts that would be reasonably likely to result in (i)&nbsp;a material Safety Notice with respect to the products of the Company or any of its Subsidiaries, (ii)&nbsp;a material change in labeling of any of the products of the Company
or any of its Subsidiaries, or (iii)&nbsp;a termination or suspension of marketing or testing of any of the products of the Company or any of its Subsidiaries, except, in each case, as would not reasonably be expected to have a Material Adverse
Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxiv)<I>&nbsp;&nbsp;&nbsp;&nbsp;</I><I>Clinical Data and Regulatory
Compliance</I>. The clinical and preclinical studies and tests conducted by the Company and its Subsidiaries and, to the knowledge of the Company, the clinical and preclinical studies conducted on behalf of or sponsored by the Company or its
Subsidiaries, were, and if still pending, are, being conducted in all material respects in accordance with all Applicable Laws, including, but not limited to, the Federal Food, Drug and Cosmetic Act and its applicable implementing regulations at 21
C.F.R. Parts 50, 54, 56, 58 and 812. Any descriptions of clinical, preclinical and other studies and tests, including any related results and regulatory status, contained in the Registration Statement, the Prospectus and any Permitted Free Writing
Prospectus are complete, accurate, and fairly represented in all material respects. Except as disclosed in the Registration Statement, the Prospectus and any Permitted Free Writing Prospectus and to the Company&#146;s knowledge, there are no
studies, tests or trials the result of which the Company believes reasonably call into question in any material respect the clinical trial results described or referred to in the Registration Statement, the Prospectus or any Permitted Free Writing
Prospectus when viewed in the context in which such results are described and the clinical state of development. No marketing authorization, including any 510(k) clearance held by the Company, has been terminated or suspended by the FDA, and neither
the FDA nor any applicable foreign regulatory agency has commenced, or, to the Company&#146;s knowledge, threatened to initiate, any action to place a clinical hold order on, or otherwise terminate, delay or suspend, any proposed or ongoing clinical
investigation conducted or proposed to be conducted by or on behalf of the Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxv)&nbsp;&nbsp;&nbsp;&nbsp; <I>Absence of Settlement Agreements or Undertakings</I>. Except as disclosed in the Registration
Statement and the Prospectus, the Company is not a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental authority. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxvi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Absence of Legal or Governmental Proceedings</I>. Except as disclosed
in the Registration Statement and the Prospectus, there are no legal or governmental proceedings pending to which the Company or any of its Subsidiaries is a party or of which any property or assets of the Company or any of its Subsidiaries is the
subject that, if determined adversely to the Company, would, in the aggregate, reasonably be expected to have a Material Adverse Effect or would, in the aggregate, reasonably be expected to have a Material Adverse Effect on the performance of this
Agreement or the consummation of the transactions contemplated hereby; and to the Company&#146;s knowledge, no such proceedings are threatened or contemplated by governmental authorities or others. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxvii) &nbsp;&nbsp;&nbsp;&nbsp;<I>Material Contracts</I>. There are no contracts or other documents required to be described
in the Registration Statement or filed as exhibits to the Registration Statement that are not described and filed as required. The statements made in the Registration Statement and Prospectus, insofar as they purport to constitute summaries of the
terms of the contracts and other documents described and filed, constitute accurate summaries of the terms of such contracts and documents in all material respects. Except as disclosed in the Registration Statement and the Prospectus, neither the
Company nor any of its Subsidiaries has knowledge that any other party to any such contract or other document has any intention not to render full performance as contemplated by the terms thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxviii)&nbsp;&nbsp;&nbsp;&nbsp; <I>Insurance</I>. The Company and each of
its Subsidiaries maintain insurance from nationally recognized, in the applicable country, insurers in such amounts and covering such risks as is commercially reasonable in accordance with customary practices for companies engaged in similar
businesses and similar industries for the conduct of their respective businesses and the value of their respective properties and as is customary for companies engaged in similar businesses in similar industries. All policies of insurance of the
Company and its Subsidiaries are in full force and effect; the Company and each of its Subsidiaries are in compliance with the terms of such policies in all material respects; and neither the Company nor any of its Subsidiaries has received notice
from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance; there are no material claims by the Company or any of its Subsidiaries under any such
policy or instrument as to which any insurance company is denying liability or defending under a reservation of rights clause; and neither the Company nor any such Subsidiary has any reason to believe that it will not be able to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxix)<I>&nbsp;&nbsp;&nbsp;&nbsp;Related Party Disclosure</I>. No relationship, direct or indirect, exists between or among the
Company, on the one hand, and the directors, officers, shareholders, customers or suppliers of the Company, on the other hand, that is required to be described in the Registration Statement or the Prospectus which is not so described. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxx)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Labor Dispute</I>. No labor disturbance by or dispute with the employees of the Company or
any of its Subsidiaries exists or, to the knowledge of the Company, is imminent that could reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxi)&nbsp;&nbsp;&nbsp;&nbsp; <I>No Default</I>. Except as disclosed in the Registration Statement and the Prospectus, neither
the Company nor any of its Subsidiaries (i)&nbsp;is in violation of its articles of association, charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> (or similar organizational documents), (ii) is in default, and no event has occurred that,
with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant, condition or other obligation contained in any indenture, mortgage, deed of trust, loan agreement, license or other
agreement or instrument to which it is a party or by which it is bound or to which any of its properties or assets is subject, or (iii)&nbsp;is in violation of any statute or any order, rule or regulation of any court or governmental agency or body
having jurisdiction over it or its property or assets or has failed to obtain any license, permit, certificate, franchise or other governmental authorization or permit necessary to the ownership of its property or to the conduct of its business,
except in the case of clauses (ii)&nbsp;and (iii), to the extent any such conflict, breach, violation or default would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxii)&nbsp;&nbsp;&nbsp;&nbsp;<I>Environmental Laws</I>. Except as set
forth in the Registration Statement or the Prospectus, the Company and its Subsidiaries (i)&nbsp;are in compliance with any and all applicable federal, state, local and foreign laws, rules, regulations, decisions and orders relating to the
protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#147;<B><I>Environmental Laws</I></B>&#148;); (ii)&nbsp;have received and are in compliance with all
permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses as described in the Registration Statement and the Prospectus; and (iii)&nbsp;have not received notice of any actual or
potential liability for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, except, in the case of any of clauses (i), (ii)&nbsp;or (iii)&nbsp;above, for any such
failure to comply or failure to receive required permits, licenses, other approvals or liability as would not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxiii)&nbsp;&nbsp;&nbsp;&nbsp;<I>Taxes</I>. The Company and each of its Subsidiaries have filed all federal, state, local and
foreign tax returns required to be filed through the date hereof, subject to permitted extensions, and have paid all taxes due, and no tax deficiency has been determined adversely to the Company or any of its Subsidiaries, nor does the Company have
any knowledge of any tax deficiencies that have been, or would reasonably be expected to be asserted against the Company, that would, in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxiv)&nbsp;&nbsp;&nbsp;&nbsp;<I>ERISA Compliance</I>. (i)&nbsp;Each &#147;employee benefit plan&#148; (within the meaning of
Section&nbsp;3(3) of the Employee Retirement Security Act of 1974, as amended (<B><I>&#147;ERISA&#148;</I></B>)) for which the Company or any member of its &#147;Controlled Group&#148; (defined as any organization which is a member of a controlled
group of corporations within the meaning of Section&nbsp;414 of the Internal Revenue Code of 1986, as amended (the <B><I>&#147;Code&#148;</I></B>)) would have any liability (each a <B><I>&#147;Plan&#148;</I></B>) has been maintained in compliance in
all material respects with its terms and with the requirements of all applicable statutes, rules and regulations including ERISA and the Code; (ii)&nbsp;no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975
of the Code, has occurred with respect to any Plan excluding transactions effected pursuant to a statutory or administrative exemption; (iii)&nbsp;with respect to each Plan subject to Title IV of ERISA (A)&nbsp;no &#147;reportable event&#148;
(within the meaning of Section&nbsp;4043(c) of ERISA) has occurred or is reasonably expected to occur that would result in a material loss to the Company, (B)&nbsp;no &#147;accumulated funding deficiency&#148; (within the meaning of Section&nbsp;302
of ERISA or Section&nbsp;412 of the Code), whether or not waived, has occurred or is reasonably expected to occur, (C)&nbsp;the fair market value of the assets under each Plan that is required to be funded exceeds the present value of all benefits
accrued under such Plan (determined based on those assumptions used to fund such Plan), and (D)&nbsp;neither the Company or any member of its Controlled Group has incurred, or reasonably expects to incur, any liability under Title IV of ERISA (other
than contributions to the Plan or premiums to the Pension Benefit Guaranty Corporation in the ordinary course and without default) in respect of a Plan (including a &#147;multiemployer plan&#148;, within the meaning of Section&nbsp;4001(c)(3) of
ERISA); and (iv)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified and nothing has occurred, to the Company&#146;s knowledge, whether by action or by failure to act, which would cause the loss of
such qualification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxv)&nbsp;&nbsp;&nbsp;&nbsp;<I>Accuracy of Statistical and Market
Data</I>. The statistical and market-related data included in the Registration Statement and the Prospectus and the consolidated financial statements of the Company and its Subsidiaries included or incorporated by reference in the Registration
Statement and the Prospectus are based on or derived from sources that the Company believes to be reliable in all material respects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxvi)&nbsp;&nbsp;&nbsp;&nbsp;<I>Not an Investment Company</I>. Neither the Company nor any of its Subsidiaries is, and as of
the applicable Settlement Date and, after giving effect to the offer and sale of the Shares and the application of the proceeds therefrom as described under &#147;Use of Proceeds&#148; in the Registration Statement and the Prospectus, none of them
will be, (i)&nbsp;an &#147;investment company&#148; or a company &#147;controlled&#148; by an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended (the <B><I>&#147;Investment Company Act&#148;</I></B>),
and the rules and regulations of the Commission thereunder, or (ii)&nbsp;a &#147;business development company&#148; (as defined in Section&nbsp;2(a)(48) of the Investment Company Act). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxvii) &nbsp;&nbsp;&nbsp;&nbsp;<I>Registration Rights</I>. Except as disclosed in the Registration Statement and the
Prospectus, there are no contracts, agreements or understandings between the Company and any person granting such person the right to require the Company to file a registration statement under the Securities Act with respect to any securities of the
Company owned or to be owned by such person. There are no contracts, agreements or understandings to require the Company to include any such securities in the securities proposed to be offered pursuant to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxviii)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Other Brokers</I>. Neither the Company nor any of its Subsidiaries is a party to any
contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against any of them or the Agent for a brokerage commission, finder&#146;s fee or like payment in connection with the offering and
sale of the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxix)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Integration</I>. The Company has not sold or issued any
securities that would be integrated with the offering of the Shares contemplated by this Agreement pursuant to the Securities Act or the interpretations thereof by the Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xl)&nbsp;&nbsp;&nbsp;&nbsp;<I>Absence of Stabilization or Manipulation</I>. The Company and its affiliates have not taken,
directly or indirectly, any action designed to or that has constituted or that could reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company in connection with the offering of the
Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xli)&nbsp;&nbsp;&nbsp;&nbsp;<I>Exchange Act Registration and Listing of the
Common Shares</I>. The Common Shares are registered pursuant to Section&nbsp;12(b) of the Exchange Act and listed on the Exchange; the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration
of the Common Shares under the Exchange Act or delisting the Common Shares from the Exchange, nor has the Company received any notification that the Commission or FINRA is contemplating terminating such registration or listing. The Common Shares are
currently listed on the Exchange under the trading symbol &#147;PSTV&#148;. Except as disclosed in the Registration Statement and the Prospectus, the Company has not, in the twelve (12)&nbsp;months preceding the date hereof, received any notice from
any Person to the effect that the Company is not in compliance with the rules and regulations of the Exchange. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in material compliance with the
rules and regulations of the Exchange. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xlii)&nbsp;&nbsp;&nbsp;&nbsp;<I>Offering Material</I>. The Company has not
distributed and prior to any Settlement Date, will not distribute any offering material in connection with any Placement (as defined in Section&nbsp;2(a)(i) below), other than the Prospectus, and any Permitted Free Writing Prospectus to which the
Agent has consented. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xliii)&nbsp;&nbsp;&nbsp;&nbsp; <I>Compliance with Labor Laws</I>. Neither the Company nor any
Subsidiary is in violation of or has received notice of any violation with respect to any federal or state law relating to discrimination in the hiring, promotion or pay of employees, nor any applicable federal or state wage and hour laws, nor any
state law precluding the denial of credit due to the neighborhood in which a property is situated, the violation of any of which could reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xliv)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Unlawful Payments</I>. Neither the Company nor any of its Subsidiaries, nor, to the
knowledge of the Company, any director, officer, agent, employee or other person associated with or acting on behalf of the Company or any of its Subsidiaries, has (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment
or other unlawful expense relating to political activity; (ii)&nbsp;made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii)&nbsp;violated or is in violation of any provision
of the U.S. Foreign Corrupt Practices Act of 1977, the Organization for Economic <FONT STYLE="white-space:nowrap">Co-operation</FONT> and Development Convention on Bribery of Foreign Public Officials in International Business Transactions, and the
rules and regulations thereunder and any other similar foreign or domestic law or regulation; or (iv)&nbsp;made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment. The Company has instituted and maintains policies and
procedures designed to ensure continued compliance with the laws and regulations referenced in clause (iii)&nbsp;of this paragraph. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xlv)&nbsp;&nbsp;&nbsp;&nbsp; <I>Anti-Money Laundering Compliance</I>. The operations of the Company and its Subsidiaries are
and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable
jurisdictions, the rules and regulations thereunder and any applicable related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the <B><I>&#147;Money Laundering
Laws&#148;</I></B>) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to the
knowledge of the Company, threatened. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xlvi)&nbsp;&nbsp;&nbsp;&nbsp;<I>OFAC Compliance</I>. Neither the Company
nor any of its Subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee or affiliate of the Company or any of its Subsidiaries is currently subject to any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department (<B><I>&#147;OFAC&#148;</I></B>); and the Company will not directly or indirectly use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any joint venture partner or
other person or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xlvii)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Taxes or Fees Due Upon Issuance</I>. No stamp, issue, registration, documentary, transfer
or other similar taxes and duties, including interest and penalties, are payable on or in connection with the issuance and sale of the Shares by the Company or the execution and delivery of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xlviii)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Immunity</I>. Neither the Company nor any Subsidiary, nor any of their respective
properties or assets, has any immunity from the jurisdiction of any court or from any legal process (whether through service or notice, attachment to prior judgment, attachment in aid of execution or otherwise) under the laws of any jurisdiction in
which it is organized, headquartered or doing business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xlix)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Legal, Accounting or Tax
Advice</I>. The Company has not relied upon the Agent or legal counsel for the Agent for any legal, tax or accounting advice in connection with the offering and sale of the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<I>Certificate as Representation and Warranty</I>. Any certificate signed by any officer of the
Company and delivered to the Agent or the Agent&#146;s counsel in connection with the offering of the Shares shall be deemed a representation and warranty by the Company to Agent as to the matters covered thereby. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>2.</I></B> <B><I>Purchase, Sale and Delivery of Shares</I></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">At-the-Market</FONT></FONT> Sales. </I>On the
basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions herein set forth, the Company agrees to issue and sell through the Agent as sales agent, and the Agent agrees to use its commercially
reasonable efforts to sell for and on behalf of the Company, the Shares on the following terms and conditions; <I>provided</I>, <I>however</I>, that any obligation of the Agent to use such commercially reasonable efforts shall be subject to the
continuing accuracy of the representations and warranties of the Company herein, the performance by the Company of its covenants and obligations hereunder and the continuing satisfaction of the additional conditions specified in Section&nbsp;4 of
this Agreement. The Company acknowledges and agrees that (i)&nbsp;there can be no assurance that the Agent will be successful in selling Shares, and (ii)&nbsp;the Agent will incur no liability or obligation to the Company or any other person or
entity if it does not sell Shares for any reason other than a failure by Agent to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such Shares as required under this Section&nbsp;2.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Each time that the Company wishes to issue and
sell the Shares hereunder (each, a <B><I>&#147;Placement&#148;</I></B>), it will notify Agent by email notice (or other method mutually agreed to in writing by the parties) (a <B><I>&#147;Placement Notice&#148;</I></B>) containing the parameters in
accordance with which it desires the Shares to be sold, which shall at a minimum include the number of Shares to be issued, the time period during which sales are requested to be made, any limitation on the number of Shares that may be sold in any
one Trading Day (as defined below) and any minimum price below which sales may not be made, a form of which containing such minimum sales parameters necessary is attached hereto as <U>Schedule 1</U>.&nbsp;The Placement Notice shall originate from
any of the individuals from the Company set forth on <U>Schedule 2</U> (with a copy to each of the other individuals from the Company listed on such schedule), and shall be addressed to each of the individuals from the relevant Agent set forth on
<U>Schedule 2</U>, as such <U>Schedule 2</U> may be amended from time to time. The Placement Notice shall be effective upon receipt by the relevant Agent unless and until (i)&nbsp;in accordance with the notice requirements set forth in
Section&nbsp;2(a)(iii) of this Agreement, such Agent declines to accept the terms contained therein for any reason, in its sole discretion, (ii)&nbsp;the entire amount of the Shares have been sold, (iii)&nbsp;the Company suspends or terminates the
Placement Notice in accordance with the notice requirements set forth in Section&nbsp;2(a)(iii) below, (iv)&nbsp;the Company issues a subsequent Placement Notice with parameters superseding those on the earlier dated Placement Notice, or
(v)&nbsp;this Agreement has been terminated under the provisions of Section&nbsp;7.&nbsp;The amount of any commission or other compensation to be paid by the Company to the relevant Agent in connection with the sale of the Shares shall be calculated
in accordance with the terms set forth in Section&nbsp;2(a)(v) below. It is expressly acknowledged and agreed that neither the Company nor the Agent will have any obligation whatsoever with respect to a Placement or any Shares unless and until the
Company delivers a Placement Notice to the Agent and such Agent does not decline such Placement Notice pursuant to the terms set forth above, and then only upon the terms specified therein and herein.&nbsp;In the event of a conflict between the
terms of this Agreement and the terms of the Placement Notice, the terms of the Placement Notice will control. For the purposes hereof, <B><I>&#147;Trading Day&#148;</I></B> means any day on which the Company&#146;s Common Shares are purchased and
sold on the principal market on which the Common Shares are listed or quoted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The Shares are
to be sold by the Agent on a daily basis or otherwise as shall be agreed to by the Company and the Agent on any day that is a trading day for the Exchange (other than a day on which the Exchange is scheduled to close prior to its regular weekday
closing time). The gross sales price of the Shares sold under this Section&nbsp;2(a) shall be the market price for the Company&#146;s Common Shares sold by the Agent under this Section&nbsp;2(a) at the time of such sale. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, the Company may
instruct the Agent by telephone (confirmed promptly by email) not to sell the Shares if such sales cannot be effected at or above the price designated by the Company in any such instruction. Furthermore, the Company shall not authorize the issuance
and sale of, and the Agent shall not be obligated to use its commercially reasonable efforts to sell, any Share at a price lower than the minimum price therefor designated from time to time by the Company&#146;s Board of Directors and notified to
the Agent in writing. In addition, the Company or Agent may, upon notice to the other party hereto by telephone (confirmed promptly by email), suspend the offering of the Shares, whereupon such Agent shall so suspend the offering of Shares until
further notice is provided to the other party to the contrary; <I>provided</I>, <I>however</I>, that such suspension or termination shall not affect or impair the parties&#146; respective obligations with respect to the Shares sold hereunder prior
to the giving of such notice. Notwithstanding any other provision of this Agreement, during any period in which the Company is in possession of material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company and the Agent agree
that (i)&nbsp;no sale of Shares will take place, (ii)&nbsp;the Company shall not request the sale of any Shares, and (iii)&nbsp;Agent shall not be obligated to sell or offer to sell any Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) &nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms of the Placement Notice, the Agent may sell the Shares by any method
permitted by law deemed to be an &#147;at the market offering&#148; as defined in Rule 415(a)(4) under the Securities Act, including sales made directly on or through the Exchange. Subject to the terms of any Placement Notice, the Agent may also
sell Shares in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices and/or any other method permitted by law, subject to the prior written consent of the Company. During the
term of this Agreement, and notwithstanding anything to the contrary herein, the Agent agrees that in no event will it or any of its affiliates engage in any market making, bidding, stabilization or other trading activity with regard to the Common
Shares if such activity would be prohibited under Regulation M or other anti-manipulation rules under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;The compensation to the Agent for sales of the Shares, as agent of the Company, shall be 3.0% of the
gross sales price of the Shares sold by such Agent pursuant to this Section&nbsp;2(a), payable in cash (the <B><I>&#147;Commission&#148;</I></B>). The remaining proceeds, after further deduction for any transaction fees imposed by any governmental
or self-regulatory organization in respect of such sales, and reimbursement of expenses that the Agent may be entitled to pursuant to Section&nbsp;3(g), shall constitute the net proceeds to the Company for such Shares (the &#147;<B><I>Net
Proceeds</I></B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;Agent will provide written confirmation to the Company (including by
email correspondence to each of the individuals of the Company set forth on <U>Schedule 2</U>), no later than the opening of the Trading Day immediately following the Trading Day on which it has made sales of Shares hereunder, setting forth the
number of Shares sold on such day, the volume-weighted average price of the Shares sold, and the Net Proceeds payable to the Company.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;All Shares sold pursuant to this
Section&nbsp;2(a) will be delivered by the Company to the relevant Agent for the account of such Agent, against payment of the Net Proceeds therefor, by wire transfer of <FONT STYLE="white-space:nowrap">same-day</FONT> funds payable to the order of
the Company at the offices of (i)&nbsp;Canaccord Genuity LLC, 99 High Street, Boston, Massachusetts 02110, or (ii)&nbsp;such other location as may be mutually acceptable, at 10:00&nbsp;a.m. Eastern Time on the second full business day following the
date on which such Shares are sold, or at such other time and date as such Agent and the Company determine pursuant to Rule <FONT STYLE="white-space:nowrap">15c6-1(a)</FONT> under the Exchange Act, each such time and date of delivery being herein
referred to as a &#147;<B><I>Settlement Date</I></B>.&#148; If the Agent so elects, delivery of the Shares may be made by credit through full fast transfer to an account or accounts at The Depository Trust Company designated by such Agent. On each
Settlement Date, such Agent will deliver the Net Proceeds in same day funds to an account designated by the Company on, or prior to, such Settlement Date.&nbsp;The Company agrees that if the Company, or its transfer agent (if applicable), defaults
in its obligation to timely deliver duly authorized Shares on a Settlement Date, the Company agrees that in addition to and in no way limiting the rights and obligations set forth in Section&nbsp;5&nbsp;hereto, it will (i)&nbsp;hold the relevant
Agent harmless against any loss, claim, damage, or expense (including reasonable legal fees and expenses), as incurred, arising out of or in connection with such default by the Company, (iii)&nbsp;reimburse such Agent for any losses incurred by the
Agent attributable, directly or indirectly, to such default and (iii)&nbsp;pay to such Agent any commission or other compensation to which such Agent would otherwise have been entitled absent such default. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii)<I>&nbsp;&nbsp;&nbsp;&nbsp;</I>During the term of this Agreement, neither Agent nor any of its affiliates or subsidiaries
shall engage in (i)&nbsp;any short sale of any security of the Company or (ii)&nbsp;any sale of any security of the Company that such Agent does not own or any sale which is consummated by the delivery of a security of the Company borrowed by, or
for the account of, such Agent. Neither Agent nor any of its affiliates or subsidiaries shall engage in any proprietary trading or trading for such Agent&#146;s (or its affiliates&#146; or subsidiaries&#146;) own account. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix)<I>&nbsp;&nbsp;&nbsp;&nbsp;</I>During the term of this Agreement, and notwithstanding anything to the contrary herein,
Agent agrees that in no event will it or any of its affiliates engage in any market making, bidding, stabilization or other trading activity with regard to the Common Shares if such activity would be prohibited under Regulation M or other
anti-manipulation rules under the Securities Act.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Maximum Amount</I>. Under no circumstances shall the
aggregate number or aggregate value of the Shares sold pursuant to this Agreement exceed: (i)&nbsp;the aggregate number and aggregate dollar amount of Common Shares available for issuance under the currently effective Registration Statement,
(ii)&nbsp;the aggregate dollar amount of Common Shares permitted to be sold under the Company&#146;s effective Registration Statement (including any limit set forth in General Instruction I.B.6 thereof, if applicable) or (iii)&nbsp;the aggregate
number or aggregate dollar amount of the Common Shares for which the Company has filed any Prospectus Supplement in connection with the Shares (the lesser of (i), (ii), and (iii) (the <I>&#147;</I><B><I>Maximum Amount</I></B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &nbsp;&nbsp;&nbsp;&nbsp;<I>No Association or Partnership</I>. Nothing herein contained
shall constitute the Agent an unincorporated association or partner with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &nbsp;&nbsp;&nbsp;&nbsp;<I>Duration</I>. Under
no circumstances shall any Shares be sold pursuant to this Agreement after the date which is three years after the Registration Statement is first declared effective by the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Market Transactions by Agent</I>. The Company acknowledges and agrees that the Agent has informed the Company
that the Agent may, to the extent permitted under the Securities Act, the Exchange Act and this Agreement, purchase and sell Common Shares for its own account while this Agreement is in effect, <I>provided, that</I> (i)&nbsp;no sale for its own
account shall take place while a Placement Notice is in effect (except to the extent the Agent may engage in sales of Shares purchased or deemed purchased from the Company as a &#147;riskless principal&#148; or in a similar capacity) and
(ii)&nbsp;the Company shall not be deemed to have authorized or consented to any such purchases or sales by the Agent. The Company consents to the Agent trading in the Common Shares for the account of any of its clients at the same time as sales of
the Shares occur pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>3.</I></B> <B><I>Covenants of the Company</I></B>. The Company covenants and agrees
with the Agent as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Amendments to Registration Statement and Prospectus</I>. After the date of this
Agreement and during any period in which a Prospectus relating to any Shares is required to be delivered by the Agent under the Securities Act (including in circumstances where such requirement may be satisfied pursuant to Rule&nbsp;172 under the
Securities Act), the Company agrees that it will: (i)&nbsp;notify the Agent promptly of the time when any subsequent amendment to the Registration Statement, other than documents incorporated by reference or amendments not related to the Shares, has
been filed with the Commission and/or has become effective or any subsequent supplement to the Prospectus related to the Shares has been filed and of any request by the Commission for any amendment or supplement to the Registration Statement
(insofar as it relates to the transactions contemplated hereby) or Prospectus or for additional information; (ii)&nbsp;prepare and file with the Commission, promptly upon the Agent&#146;s request, any amendments or supplements to the Registration
Statement or Prospectus that, in the Agent&#146;s reasonable opinion, may be necessary or advisable in connection with the sale of the Shares by the Agent (<I>provided, however</I>, that the failure of the Agent to make such request shall not
relieve the Company of any obligation or liability hereunder, or affect the Agent&#146;s right to rely on the representations and warranties made by the Company in this Agreement); (iii)&nbsp;not file any amendment or supplement to the Registration
Statement or Prospectus, other than documents incorporated by reference, relating to the Shares or a security convertible into the Shares unless a copy thereof has been submitted to the Agent within a reasonable period of time before the filing and
the Agent has not reasonably objected thereto (<I>provided, however</I>, that (A)&nbsp;the failure of the Agent to make such objection shall not relieve the Company of any obligation or liability hereunder, or affect the Agent&#146;s right to rely
on the representations and warranties made by the Company in this Agreement), (B)&nbsp;the Company has no obligation to provide the Agent any advance copy of such filing or to provide the Agent an opportunity to object to such filing if the filing
does not name the Agent or does not relate to a Placement or other transaction contemplated hereunder, and (C)&nbsp;the only remedy that the Agent shall have with respect to the failure by the Company to provide the Agent with such copy or the
filing of such amendment or supplement despite the Agent&#146;s objection shall be to cease making sales under this Agreement); (iv) furnish to the Agent at the time of filing thereof a copy of any document that upon filing is deemed to be
incorporated by reference into the Registration Statement or Prospectus, except for those documents available via EDGAR; and (iv)&nbsp;cause each amendment or supplement to the Prospectus, other than documents incorporated by reference, to be filed
with the Commission as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Stop Order</I>. The Company will advise the Agent, promptly
after it receives notice or obtains knowledge thereof, of the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement, of the suspension of the qualification of the Shares for
offering or sale in any jurisdiction, or of the initiation or threatening of any proceeding for any such purpose, and it will promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal if
such a stop order should be issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Continuing Amendments</I>. During any period in which a Prospectus
relating to the Shares is required to be delivered by the Agent under the Securities Act with respect to any Placement or pending sale of the Shares, (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the
Securities Act), the Company will comply with all requirements imposed upon it by the Securities Act, as from time to time in force, and to file on or before their respective due dates all reports (taking into account any extensions available under
the Exchange Act) and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange Act. If during such period any
event occurs as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances then
existing, not misleading, or if during such period it is necessary to amend or supplement the Registration Statement or Prospectus to comply with the Securities Act, the Company will promptly notify the Agent to suspend the offering of Shares during
such period and the Company will promptly amend or supplement the Registration Statement or Prospectus (at the expense of the Company) so as to correct such statement or omission or effect such compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Qualification of the Shares</I>. The Company shall take or cause to be taken all necessary action to qualify the
Shares for sale under the securities laws of such jurisdictions as the Agent reasonably designates and to continue such qualifications in effect so long as required for the distribution of the Shares, except that the Company shall not be required in
connection therewith to qualify as a foreign corporation or to execute a general consent to service of process in any state. The Company shall promptly advise the Agent of the receipt by the Company of any notification with respect to the suspension
of the qualification of the Shares for offer or sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Copies of Registration Statement and Prospectus</I>. The Company will furnish to the Agent and counsel for the
Agent copies of the Registration Statement (which will include three complete manually signed copies of the Registration Statement and all consents and exhibits filed therewith), the Prospectus and all amendments and supplements to such documents,
in each case as soon as available and in such quantities as the Agent may from time to time reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<I>Section 11(a)</I>. The Company will make generally available
to its security holders as soon as practicable an earnings statement (which need not be audited) covering a <FONT STYLE="white-space:nowrap">12-month</FONT> period that shall satisfy the provisions of Section&nbsp;11(a) of the Securities Act and
Rule&nbsp;158 promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<I>Expenses</I>. The Company, whether or not the transactions
contemplated hereunder are consummated or this Agreement is terminated, will pay or cause to be paid (i)&nbsp;all expenses (including stock or transfer taxes and stamp or similar duties allocated to the respective transferees) incurred in connection
with the registration, issue, sale and delivery of the Shares, (ii)&nbsp;all expenses and fees (including, without limitation, fees and expenses of the Company&#146;s accountants and counsel) in connection with the preparation, printing, filing,
delivery, and shipping of the Registration Statement (including the financial statements therein and all amendments, schedules, and exhibits thereto), the Shares, the Prospectus and any amendment thereof or supplement thereto, and the producing,
word-processing, printing, delivery, and shipping of this Agreement and other underwriting documents or closing documents, including Blue Sky Memoranda (covering the states and other applicable jurisdictions) and including the cost to furnish copies
of each thereof to the Agent, (iii)&nbsp;all filing fees, (iv)&nbsp;all fees and disbursements of the Agent&#146;s counsel incurred in connection with the qualification of the Shares for offering and sale by the Agent or by dealers under the
securities or blue sky laws of the states and other jurisdictions which Agent shall designate, (v)&nbsp;the fees and expenses of any transfer agent or registrar, (vi)&nbsp;the filing fees and fees and disbursements of Agent&#146;s counsel incident
to any required review and approval by FINRA of the terms of the sale of the Shares, (vii)&nbsp;listing fees, if any, (viii)&nbsp;the cost and expenses of the Company relating to investor presentations or any &#147;roadshow&#148; undertaken in
connection with marketing of the Shares, and (ix)&nbsp;all other costs and expenses incident to the performance of its obligations hereunder that are not otherwise specifically provided for herein. The Company agrees to reimburse the reasonable fees
and disbursements of Agent&#146;s counsel (A)&nbsp;in the amount of $50,000 upon execution of this Agreement, (B)&nbsp;incurred on a quarterly basis after the date of this Agreement for the purposes of maintaining the Company&#146;s ability to sell
Shares pursuant to this Agreement, and (C)&nbsp;incurred in connection with any reapplication or maintenance filing of a Form <FONT STYLE="white-space:nowrap">S-3</FONT> shelf registration statement and/or applicable prospectus supplement that
replaces the Registration Statement or supplements the Prospectus Supplement, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<I>Use of
Proceeds</I>. The Company will apply the net proceeds from the sale of the Shares in the manner set forth in the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>Restrictions on Future Sales</I>. During the term of this Agreement, without giving the Agent at least two
business days&#146; prior email notice (or other method mutually agreed to in writing by the parties) specifying the nature of the proposed sale or disposition so as to permit the Agent to suspend activity under this Agreement for such period of
time as requested by the Company the Company will not (i)&nbsp;directly or indirectly, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares (other than the Shares offered pursuant to this
Agreement) or securities convertible into or exchangeable for Common Shares, warrants or any rights to purchase or acquire Common Shares during the period beginning on the fifth (5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) Trading Day
immediately prior to the date on which any Placement Notice is delivered to the Agent hereunder and ending on the fifth (5th) Trading Day immediately following the final Settlement Date with respect to Shares sold pursuant to such Placement Notice
(or, if the Placement Notice has been terminated or suspended prior to the sale of all Shares covered by a Placement Notice, the date of such suspension or termination); or (ii)&nbsp;directly or indirectly in any other
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT> or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares
(other than the Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Common Shares, warrants or any rights to purchase or acquire, Common Shares prior to the later of the termination of this Agreement and the
sixtieth (60th) day immediately following the final Settlement Date with respect to Shares sold pursuant to such Placement Notice; <I>provided</I>, <I>however</I>, that such restrictions will not be required in connection with the Company&#146;s
issuance or sale (either directly or indirectly) of (i)&nbsp;Common Shares, options to purchase Common Shares or Common Shares issuable upon the exercise of options, pursuant to any employee or director stock option or benefits plan, stock ownership
plan or dividend reinvestment plan (but not Common Shares subject to a waiver to exceed plan limits in its dividend reinvestment plan) of the Company whether now in effect or hereafter implemented, (ii)&nbsp;Common Shares issuable upon conversion of
securities or the exercise of warrants, options or other rights in effect or outstanding, and disclosed in filings by the Company available on EDGAR or otherwise in writing to the Agent; (iii)&nbsp;Common Shares or securities convertible into or
exchangeable for Common Shares as consideration for mergers, acquisitions, other business combinations or strategic alliances, or offered and sold in a privately negotiated transaction to vendors, customers, lenders, investors, strategic partners or
potential strategic partners, occurring after the date of this Agreement which are not issued primarily for capital raising purposes; (iv)&nbsp;shares of Common Stock pursuant to the Purchase Agreement dated as of August&nbsp;2, 2022, between
Lincoln Park Capital Fund, LLC and the Company, provided in the case of this clause (iv)&nbsp;there is no pending Placement Notice and the Company has provided the Agent with prior email notice (or other method mutually agreed to in writing by the
parties) of such proposed sale; and (v)&nbsp;the Shares offered pursuant to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Stabilization or Manipulation</I>. The Company has not
taken and will not take, directly or indirectly, any action designed to, or which might reasonably be expected to cause or result in, or which constitutes: (i)&nbsp;the stabilization or manipulation of the price of the Common Shares or any other
security of the Company to facilitate the sale or resale of the Shares, (ii)&nbsp;a violation of Regulation M. The Company shall notify the Agent of any violation of Regulation M by the Company or any of its Subsidiaries or any of their respective
officers or directors promptly after the Company has received notice or obtained knowledge of any such violation. The Company shall not invest in futures contracts, options on futures contracts or options on commodities, unless the Company is exempt
from the registration requirements of the Commodity Exchange Act, as amended (the <B><I>&#147;Commodity Act&#148;</I></B>), or otherwise complies with the Commodity Act. The Company will not engage in any activities bearing on the Commodity Act,
unless such activities are exempt from the Commodity Act or otherwise comply with the Commodity Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Other Broker</I>. The Company will not incur any liability for any finder&#146;s or broker&#146;s fee or agent&#146;s commission in connection with the execution and delivery of this Agreement, or the consummation of the transactions contemplated
hereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<I>Timely Securities Act and Exchange Act Reports</I>. During any
prospectus delivery period, the Company will use its commercially reasonable efforts to file on a timely basis with the Commission such periodic and special reports as required by the Securities Act and the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<I>Internal Controls</I>. The Company and its Subsidiaries will maintain such controls and other procedures,
including without limitation, those required by Sections 302 and 906 of the Sarbanes-Oxley Act and the applicable regulations thereunder, that are designed to ensure that information required to be disclosed by the Company in the reports that it
files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#146;s rules and forms, including without limitation, controls and procedures designed to ensure that
information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&#146;s management, including its principal executive officer and its principal
financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure, to ensure that material information relating to Company, including its Subsidiaries, is made known to them by others
within those entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<I>Permitted Free Writing Prospectus</I>. The Company represents and agrees that,
unless it obtains the prior written consent of the Agent, and the Agent represents and agrees that, unless it obtains the prior written consent of the Company, Agent has not made and will not make any offer relating to the Shares that would
constitute an &#147;issuer free writing prospectus,&#148; as defined in Rule 433 under the Securities Act, or that would otherwise constitute a &#147;free writing prospectus,&#148; as defined in Rule 405 under the Securities Act, required to be
filed with the Commission. Any such free writing prospectus consented to by the Company and the Agent is hereinafter referred to as a <B><I>&#147;</I></B><B><I>Permitted Free Writing Prospectus.</I></B><B><I>&#148;</I></B> The Company represents
that it has treated or agrees that it will treat each Permitted Free Writing Prospectus as an &#147;issuer free writing prospectus,&#148; as defined in Rule 433, and has complied and will comply with the requirements of Rule 433 applicable to any
Permitted Free Writing Prospectus, including timely Commission filing where required, legending and record keeping. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o)
&nbsp;&nbsp;&nbsp;&nbsp;<I>Representation Date and Opinion of Counsel</I>. Prior to the date of the first Placement Notice, and thereafter during the term of this Agreement, each time the Company (A)&nbsp;files an amendment to the Registration
Statement or Prospectus (other than relating solely to the offering of securities other than the Shares), (B) files an annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> under the Exchange Act or files its quarterly reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> under the Exchange Act; and (C)&nbsp;files a report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> containing amended financial statements (other than an earnings release) under the Exchange Act, (each of
the dates in (A), (B) and (C)&nbsp;are referred to herein as a &#147;<B><I>Representation Date</I></B>&#148;), the Company shall cause Hogan Lovells US LLP, counsel for the Company, to furnish to the Agent the opinion and negative assurance
statement of such counsel, dated as of such date and addressed to Agent, in form and substance reasonably satisfactory to the Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the requirement to provide counsel opinions under this Section&nbsp;3(o)&nbsp;shall be waived for any
Representation Date occurring at a time at which no Placement Notice is pending, which waiver shall continue until the date the Company delivers a Placement Notice to the Agent.&nbsp;Notwithstanding the foregoing, if the Company subsequently decides
to sell Shares following a Representation Date when the Company relied on such waiver and did not provide the Agent with opinions under this Section&nbsp;3(o), then before the Agent sells any Shares pursuant to Section&nbsp;2(a), the Company shall
cause the opinions (including the opinion pursuant to Section&nbsp;3(o) if not delivered on the date of the prior Form <FONT STYLE="white-space:nowrap">10-K),</FONT> comfort letter, certificates and documents that would be delivered on a
Representation Date to be delivered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;<I>Representation Date and</I> <I>Comfort Letter</I>. Prior to
the date of the first Placement Notice and thereafter during the term of this Agreement, on each Representation Date to which a waiver does not apply, the Company shall cause BDO USA, LLP, or other independent accountants satisfactory to the Agent
(the &#147;<B><I>Accountants</I></B>&#148;), to deliver to the Agent a letter, dated as of such date and addressed to Agent, confirming that they are independent public accountants within the meaning of the Securities Act and are in compliance with
the applicable requirements relating to the qualifications of accountants under <FONT STYLE="white-space:nowrap">Rule&nbsp;2-01</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> of the Commission, and stating the conclusions and
findings of said firm with respect to the financial information and other matters covered by its letter in form and substance satisfactory to the Agent of the same tenor as the first such letter received hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q)&nbsp;&nbsp;&nbsp;&nbsp;<I>Representation Date and Representation Certificate</I>. Prior to the date of the First Placement Notice and
thereafter during the term of this Agreement, on each Representation Date to which a waiver does not apply, the Company shall furnish to the Agent a certificate (the <B><I>&#147;</I></B><B><I>Representation Certificate</I></B><B><I>&#148;</I></B>),
substantially in the form of <U>Schedule 3</U> and dated as of such date, addressed to the Agent and signed by the chief executive officer and by the chief financial or chief accounting officer of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r)&nbsp;&nbsp;&nbsp;&nbsp;<I>Disclosure of Shares Sold</I>. The Company shall disclose in its quarterly reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> and in its annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> the number of the Shares sold through the Agent under this Agreement, the net proceeds to the Company and the compensation paid by
the Company with respect to sales of the Shares pursuant to this Agreement during the relevant quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s)&nbsp;&nbsp;&nbsp;&nbsp;<I>Continued Listing of Shares</I>. The Company shall use its commercially reasonable efforts to maintain the
listing of the Common Shares on the Exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t)<I>&nbsp;&nbsp;&nbsp;&nbsp;</I><I></I><I></I><I></I><I>Notice of Changes</I>. At any
time during the term of this Agreement, as supplemented from time to time, the Company shall advise the Agent immediately after it shall have received notice or obtain knowledge thereof, of any information or fact that would alter or affect any
opinion, certificate, letter and other document provided to the Agent pursuant to this Section&nbsp;3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(u)
&nbsp;&nbsp;&nbsp;&nbsp;<I>Maximum Amount</I>. The Company will not instruct the Agent to sell or otherwise attempt to sell Shares in excess of the Maximum Amount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>4.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Conditions of Agent&#146;s
Obligations</I></B>. The obligations of the Agent hereunder are subject to (i)&nbsp;the accuracy, as of the Effective Time, each Representation Date, each Time of Sale, and each Filing Date (in each case, as if made at such date) of and compliance
with all representations, warranties and agreements of the Company contained herein, (ii)&nbsp;the performance by the Company of its obligations hereunder and (iii)&nbsp;the following additional conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Continuing Amendments; No Stop Order</I>. If filing of the Prospectus, or any amendment or supplement thereto,
or any Permitted Free Writing Prospectus, is required under the Securities Act, the Company shall have filed the Prospectus (or such amendment or supplement) or such Permitted Free Writing Prospectus with the Commission in the manner and within the
time period so required (without reliance on Rule 424(b)(8) or Rule 164(b)); the Registration Statement shall be effective; no stop order suspending the effectiveness of the Registration Statement or any part thereof, any Rule 462(b) Registration
Statement, or any amendment thereof, nor suspending or preventing the use of the Prospectus shall have been issued; no proceedings for the issuance of such an order shall have been initiated or threatened; and any request of the Commission for
additional information (to be included in the Registration Statement, the Prospectus or otherwise) shall have been complied with to the Agent&#146;s satisfaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Absence of Certain Events</I>. None of the following events shall have occurred and be continuing:
(i)&nbsp;receipt by the Company or any of its Subsidiaries of any request for additional information from the Commission or any other federal or state governmental authority during the period of effectiveness of the Registration Statement, the
response to which would require any post-effective amendments or supplements to the Registration Statement or the Prospectus; (ii)&nbsp;the issuance by the Commission or any other federal or state governmental authority of any stop order suspending
the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iii)&nbsp;receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any
of the Shares for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; (iv)&nbsp;the occurrence of any event that makes any material statement made in the Registration Statement or the Prospectus or any
material document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires the making of any changes in the Registration Statement, related Prospectus or such documents so that, in the case of
the Registration Statement, it will not contain any materially untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading and, that in the case of
the Prospectus, it will not contain any materially untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they
were made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Material Misstatement or Omission</I>. The Agent shall not have advised the
Company that the Registration Statement or any the Prospectus, contains an untrue statement of fact which, in the Agent&#146;s opinion, is material, or omits to state a fact which, in the Agent&#146;s opinion, is material and is required to be
stated therein or necessary to make the statements therein not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Adverse Changes</I>. Except
as contemplated in the Prospectus, subsequent to the respective dates as of which information is given in the Prospectus, neither the Company nor any of its Subsidiaries shall have incurred any material liabilities or obligations, direct or
contingent, or entered into any material transactions, or declared or paid any dividends or made any distribution of any kind with respect to its capital stock; and there shall not have been any change in the capital stock (other than a change in
the number of outstanding Common Shares due to the issuance of shares upon the exercise of outstanding options or warrants), or any material change in the <FONT STYLE="white-space:nowrap">short-term</FONT> or
<FONT STYLE="white-space:nowrap">long-term</FONT> debt of the Company, or any issuance of options, warrants, convertible securities or other rights to purchase the capital stock of the Company or any of its Subsidiaries, or any development involving
a prospective Material Adverse Effect (whether or not arising in the ordinary course of business), or any loss by strike, fire, flood, earthquake, accident or other calamity, whether or not covered by insurance, incurred by the Company or any
Subsidiary, the effect of which, in any such case described above, in the Agent&#146;s judgment, makes it impractical or inadvisable to offer or deliver the Shares on the terms and in the manner contemplated in the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Compliance with Certain Obligations</I>. The Company shall
have performed each of its obligations under Sections 3(o) &#150; 3(q). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &nbsp;&nbsp;&nbsp;&nbsp;<I>Negative Assurance of Agent
Counsel</I>. On each Representation Date to which a waiver does not apply, there shall have been furnished to the Agent the negative assurance letter of Goodwin Procter LLP, counsel for the Agent, dated as of such Representation Date and addressed
to Agent, in a form reasonably satisfactory to the Agent, and such counsel shall have received such papers and information as they request to enable them to pass upon such matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<I>Representation Certificate</I>. On or prior to the first Placement Notice, the Agent shall have received the
Representation Certificate in form and substance satisfactory to the Agent and its counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Objection by
FINRA</I>. The Financial Industry Regulatory Authority, Inc. shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>Timely Filing of Prospectus and Prospectus Supplement</I>. All filings with the Commission required by Rule 424
under the Securities Act to have been filed by the Settlement Date, as the case may be, shall have been made within the applicable time period prescribed for such filing by Rule 424. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<I>Additional Documents and Certificates</I>. The Company shall have furnished to Agent and the Agent&#146;s
counsel such additional documents, certificates and evidence as they may have reasonably requested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">All opinions, certificates, letters
and other documents described in this Section&nbsp;4 will be in compliance with the provisions hereof only if they are satisfactory in form and substance to Agent and the Agent&#146;s counsel. The Company will furnish Agent with such conformed
copies of such opinions, certificates, letters and other documents as Agent shall reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>5.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Indemnification and Contribution</I></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Company Indemnification</I>. The Company agrees to indemnify and hold harmless the Agent, its affiliates,
directors, officers and employees, and each person, if any, who controls the Agent within the meaning of Section&nbsp;15 of the Act or Section&nbsp;20 of the Exchange Act against any losses, claims, damages or liabilities, joint or several, to which
Agent may become subject, under the Securities Act or otherwise (including in settlement of any litigation), insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon, in whole or in part:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &nbsp;&nbsp;&nbsp;&nbsp;an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement,
including the Rule 430B Information and at any subsequent time pursuant to Rules&nbsp;430A and 430B promulgated under the Securities Act, and any other information deemed to be part of the Registration Statement at the time of effectiveness, and at
any subsequent time pursuant to the Securities Act or the Exchange Act, and the Prospectus, or any amendment or supplement thereto (including any documents filed under the Exchange Act and deemed to be incorporated by reference into the Prospectus),
any Permitted Free Writing Prospectus, or any roadshow as defined in Rule 433(h) under the Act (a <B><I>&#147;road show&#148;</I></B>), or an omission or alleged omission to state therein a material fact required to be stated therein or necessary to
make the statements therein not misleading, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) &nbsp;&nbsp;&nbsp;&nbsp;any inaccuracy in the representations and warranties of the
Company contained herein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any investigation or proceeding by any governmental
authority, commenced or threatened (whether or not the Agent is a target of or party to such investigation or proceeding); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)
&nbsp;&nbsp;&nbsp;&nbsp;any failure of the Company to perform its respective obligations hereunder or under law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and will reimburse the Agent for any
legal or other expenses reasonably incurred by it in connection with investigating or defending against such loss, claim, damage, liability or action; <I>provided, however,</I> that the Company shall not be liable in any such case of
(i)&nbsp;through (iv) to the extent that any such loss, claim, damage, liability or action arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement, the
Prospectus, or any such amendment or supplement, in reliance upon and in conformity with written information furnished to the Company by Agent specifically for use in the preparation thereof. &#147;<B><I>Rule 430B Information</I></B>,&#148; as used
herein, means information with respect to the Shares and the offering thereof permitted to be omitted from the Registration Statement when it becomes effective pursuant to Rule 430B. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In addition to its other obligations under this Section&nbsp;5(a), the Company agrees that, as an interim measure during the pendency of any
claim, action, investigation, inquiry or other proceeding arising out of or based upon any statement or omission, or any alleged statement or omission, described in this Section&nbsp;5(a), it will reimburse the Agent on a monthly basis for all
reasonable legal fees or other expenses incurred in connection with investigating or defending any such claim, action, investigation, inquiry or other proceeding, notwithstanding the absence of a judicial determination as to the propriety and
enforceability of the Company&#146;s obligation to reimburse the Agent for such expenses and the possibility that such payments might later be held to have been improper by a court of competent jurisdiction. Any such interim reimbursement payments
which are not made to the Agent within 30 days of a request for reimbursement shall bear interest at the WSJ Prime Rate (as published from time to time by the Wall Street Journal). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Agent Indemnification</I>. The Agent will indemnify and hold
harmless the Company against any losses, claims, damages or liabilities to which the Company may become subject, under the Securities Act or otherwise (including in settlement of any litigation, if such settlement is effected with the written
consent of the Agent), but only insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in the Registration
Statement, the Prospectus, any amendment or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not
misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in conformity with written information furnished to the Company by the Agent specifically
for use in the preparation thereof, it being understood and agreed that the only information furnished by the Agent for use in the Registration Statement or the Prospectus consists of the statements set forth in the seventh paragraph under the
caption &#147;Plan of Distribution&#148; in the Prospectus, and will reimburse the Company for any legal or other expenses reasonably incurred by the Company in connection with investigating or defending against any such loss, claim, damage,
liability or action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Notice and Procedures</I>. Promptly after receipt by an indemnified party under
subsection (a)&nbsp;or (b) above of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of
the commencement thereof; but the omission so to notify the indemnifying party shall not relieve the indemnifying party from any liability that it may have to any indemnified party except to the extent such indemnifying party has been materially
prejudiced by such failure. In case any such action shall be brought against any indemnified party, and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate in, and, to the
extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party, and after notice from the indemnifying party to such indemnified
party of the indemnifying party&#146;s election so to assume the defense thereof, the indemnifying party shall not be liable to such indemnified party under such subsection for any legal or other expenses subsequently incurred by such indemnified
party in connection with the defense thereof other than reasonable costs of investigation; <I>provided</I>, <I>however</I>, that if, in the sole judgment of the Agent, it is advisable for the Agent to be represented by separate counsel, the Agent
shall have the right to employ a single counsel to represent the Agent, in which event the reasonable fees and expenses of such separate counsel shall be borne by the indemnifying party or parties and reimbursed to the Agent as incurred (in
accordance with the provisions of the second paragraph in subsection (a)&nbsp;above). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The indemnifying party under this Section&nbsp;5
shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party
against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party
for fees and expenses of counsel as contemplated by this Section&nbsp;5, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more
than 30 days after receipt by such indemnifying party of the aforesaid request, (ii)&nbsp;such indemnifying party shall have received notice of the terms of such settlement at least 30 days prior to such settlement being entered into, and
(iii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect
any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by
such indemnified party, unless such settlement, compromise or consent (a)&nbsp;includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding and (b)&nbsp;does
not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Contribution; Limitations on Liability; <FONT
STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedy</I>. If the indemnification provided for in this Section&nbsp;5 is unavailable or insufficient to hold harmless an indemnified party under subsection&nbsp;(a) or (b)&nbsp;above, then each
indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of the losses, claims, damages or liabilities referred to in subsection&nbsp;(a) or (b)&nbsp;above, (i)&nbsp;in such proportion as is appropriate
to reflect the relative benefits received by the Company on the one hand and the Agent on the other from the offering of the Shares, or (ii)&nbsp;if the allocation provided by clause&nbsp;(i) above is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in clause&nbsp;(i) above but also the relative fault of the Company on the one hand and the Agent on the other in connection with the statements or omissions that
resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Agent on the other shall be deemed to be in the same proportion as
the total net proceeds from the offering (before deducting expenses) received by the Company bear to the total commissions received by the Agent (before deducting expenses) from the sale of the Shares. The relative fault shall be determined by
reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or the Agent, the intent of the parties
and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement or omission. The Company and the Agent agree that it would not be just and equitable if contributions pursuant to this
subsection&nbsp;(d) were to be determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in this subsection&nbsp;(d). The amount paid or payable by an indemnified
party as a result of the losses, claims, damages or liabilities referred to in this subsection&nbsp;(d) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or
defending against any action or claim which is the subject of this subsection&nbsp;(d). Notwithstanding the provisions of this subsection&nbsp;(d), the Agent shall not be required to contribute any amount in excess of the commissions received by it
under this Agreement. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>6.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Representations and Agreements to Survive
Delivery</I></B>. All representations, warranties, and agreements of the Company herein or in certificates delivered pursuant hereto, including but not limited to the agreements of the Agent and the Company contained in Section&nbsp;5 hereof, shall
remain operative and in full force and effect regardless of any investigation made by or on behalf of the Agent or any controlling person thereof, or the Company or any of its officers, directors, or controlling persons, and shall survive delivery
of, and payment for, the Shares to and by the Agent hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>7.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Termination of this
Agreement. </I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have the right, by giving ten (10)&nbsp;days&#146; written notice as
hereinafter specified, to terminate the provisions of this Agreement relating to the solicitation of offers to purchase the Shares in its sole discretion at any time. Any such termination shall be without liability of any party to any other party
except that (i)&nbsp;with respect to any pending sale, through the Agent for the Company, the obligations of the Company, including in respect of compensation of the Agent, shall remain in full force and effect notwithstanding the termination and
(ii)&nbsp;the provisions of Section&nbsp;3(g) Section&nbsp;5 and Section&nbsp;6 of this Agreement shall remain in full force and effect notwithstanding such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Agent shall have the right, by giving ten (10)&nbsp;days written notice as hereinafter specified, to terminate the
provisions of this Agreement solely with respect to such agent relating to the solicitation of offers to purchase the Shares in its sole discretion at any time. Any such termination shall be without liability of any party to any other party except
that the provisions of Section&nbsp;3(g) Section&nbsp;5 and Section&nbsp;6 of this Agreement shall remain in full force and effect notwithstanding such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Unless earlier terminated pursuant to this Section&nbsp;7, this Agreement shall automatically terminate upon the
issuance and sale of all of the Shares through the Agent on the terms and subject to the conditions set forth herein, except that the provisions of Section&nbsp;3(g) Section&nbsp;5 and Section&nbsp;6 of this Agreement shall remain in full force and
effect notwithstanding such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall remain in full force and effect unless
terminated pursuant to Sections 7(a), (b) or (c)&nbsp;above or otherwise by mutual agreement of the parties; provided that any such termination by mutual agreement shall in all cases be deemed to provide that Section&nbsp;3(g), Section&nbsp;5 and
Section&nbsp;6 shall remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Any termination of this Agreement shall be effective on
the date specified in such notice of termination; provided that such termination shall not be effective until the close of business on the date of receipt of such notice by the Agent or the Company, as the case may be. If such termination shall
occur prior to the Settlement Date for any sale of the Shares, such sale shall settle in accordance with the provisions of Section&nbsp;2(a)(vii) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>8.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Default by the Company</I></B>. If the Company shall fail at any Settlement Date to sell and
deliver the number of Shares which it is obligated to sell hereunder, then this Agreement shall terminate without any liability on the part of the Agent or, except as provided in Section&nbsp;3(g) hereof, any
<FONT STYLE="white-space:nowrap">non-defaulting</FONT> party. No action taken pursuant to this Section shall relieve the Company from liability, if any, in respect of such default, and the Company shall (A)&nbsp;hold the Agent harmless against any
loss, claim or damage arising from or as a result of such default by the Company and (B)&nbsp;pay the Agent any commission to which it would otherwise be entitled absent such default. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>9.</I></B><B><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></B><B><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></B><B><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></B><B><I>&nbsp;
&nbsp;&nbsp;&nbsp;</I></B><B><I>Notices</I></B>. Except as otherwise provided herein, all communications under this Agreement shall be in writing and shall be delivered via overnight delivery services (i)&nbsp;if to the Agent, at 99 High Street
Boston, Massachusetts 02110, Attention: General Counsel; and (ii)&nbsp;if to the Company, at 4200 Marathon Blvd., Suite 200, Austin, Texas 78756, Attention: Chief Executive Officer; or in each case to such other address as the person to be notified
may have requested in writing. Any party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>10.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Persons Entitled to Benefit of Agreement</I></B>. This Agreement shall inure to the benefit of
and be binding upon the parties hereto and their respective successors and assigns and the controlling persons, officers and directors referred to in Section&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;Nothing in this Agreement is intended or shall be construed
to give to any other person, firm or corporation any legal or equitable remedy or claim under or in respect of this Agreement or any provision herein contained. The term &#147;successors and assigns&#148; as herein used shall not include any
purchaser, as such purchaser, of any of the Shares from the Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>11.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Absence of Fiduciary
Relationship</I></B>. The Company, having been advised by counsel, acknowledges and agrees that: (a)&nbsp;the Agent has been retained solely to act as a sales agent in connection with the sale of the Shares and that no fiduciary, advisory or agency
relationship between the Company (including any of the Company&#146;s affiliates (including directors), equity holders, creditors, employees or agents, hereafter, <B><I>&#147;Company Representatives&#148;</I></B>), on the one hand, and the Agent on
the other, has been created or will be created in respect of any of the transactions contemplated by this Agreement, irrespective of whether the Agent has advised or is advising the Company on other matters and irrespective of the use of the defined
term &#147;Agent;&#148; (b) neither of the Agent nor any of its affiliates (including directors), equity holders, creditors, employees or agents, hereafter, <B><I>&#147;Agent Representatives&#148;</I></B>) shall have any duty or obligation to the
Company or any Company Representative except as set forth in this Agreement; (b)&nbsp;the price and other terms of any Placement executed pursuant to this Agreement, as well as the terms of this Agreement, are deemed acceptable to the Company and
its counsel, following discussions and arms-length negotiations with the Agent; (c)&nbsp;the Company is capable of evaluating and understanding, and in fact has evaluated, understands and accepts the terms, risks and conditions of any Placement to
be executed pursuant to this Agreement, and any other transactions contemplated by this Agreement; (c)&nbsp;the Company has been advised that the Agent and the Agent Representatives are engaged in a broad range of transactions which may involve
interests that differ from those of the Company and that the Agent and the Agent Representatives have no obligation to disclose any such interests and transactions to the Company by virtue of any fiduciary, advisory or agency relationship, or
otherwise; (d)&nbsp;the Company has been advised that the Agent is acting, in respect of any Placement and the transactions contemplated by this Agreement, solely for the benefit of the Agent, and not on behalf of the Company; and (e)&nbsp;the
Company and the Company Representatives waive, to the fullest extent permitted by law, any claims that they may have against the Agent or any of the Agent Representatives for breach of fiduciary duty or alleged breach of fiduciary duty in respect of
any Placement or any of the transactions contemplated by this Agreement and agree that the Agent and the Agent Representatives shall have no liability (whether direct or indirect, in contract, tort or otherwise) to the Company or any of the Company
Representatives in respect of any person asserting any claim of breach of any fiduciary duty on behalf of or in right of the Company or any of the Company Representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>12.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Governing Law and Waiver of Jury
Trial</I></B>. This Agreement shall be governed by and construed in accordance with the laws of the State of New York. THE COMPANY (ON ITS OWN BEHALF AND ON BEHALF OF ITS STOCKHOLDERS AND AFFILIATES) HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>13. </I></B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Submission to Jurisdiction, Etc.</I></B> Each party hereby submits to the exclusive
jurisdiction of the U.S. federal and New York state courts sitting in the Borough of Manhattan, City of New York, in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. The parties hereby
irrevocably and unconditionally waive any objection to the laying of venue of any lawsuit, action or other proceeding in such courts, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any
such lawsuit, action or other proceeding brought in any such court has been brought in an inconvenient forum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>14.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Counterparts</I></B>. This Agreement may be executed in one or more counterparts, each of which
shall be deemed an original, and all of which together shall constitute one and the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Construction.</I></B> The section and exhibit&nbsp;headings herein are for convenience only and shall not
affect the construction hereof. References herein to any law, statute, ordinance, code, regulation, rule or other requirement of any governmental authority shall be deemed to refer to such law, statute, ordinance, code, regulation, rule or other
requirement of any governmental authority as amended, reenacted, supplemented or superseded in whole or in part and in effect from time to time and also to all rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please sign and return to the Company the enclosed duplicates of this letter whereupon this
letter will become a binding agreement between the Company and the Agent in accordance with its terms. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PLUS THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Sims</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Andrew Sims</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Vice President&nbsp;&amp; Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Confirmed as of the date first above mentioned: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CANACCORD GENUITY LLC </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Jennifer Pardi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Pardi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Managing Director</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM&nbsp;OF PLACEMENT NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Via Email Only </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(No
Facsimile / No Voicemail) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">From:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Plus Therapeutics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">To:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Canaccord Genuity LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attention:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian O&#146;Connor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">boconnor@cgf.com</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Wright</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">mwright@cgf.com</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Pardi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">jpardi@cgf.com</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AND</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CGUSEcm@cgf.com</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subject:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity Distribution Agreement &#150; Placement Notice</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies / Gentlemen:&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms and subject to the conditions contained in the Equity Distribution Agreement between Plus Therapeutics, Inc., a Delaware corporation
(&#147;<B>Company</B>&#148;), and Canaccord Genuity LLC (the &#147;<B>Agent</B>&#148;) dated September&nbsp;9, 2022 (the &#147;<B>Agreement</B>&#148;),&nbsp;the Company hereby requests that Agent sell up to
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares of the Company&#146;s common stock, $0.001 par value per share, at a minimum market price of
$[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] per share.&nbsp;Sales should begin on the date of this Placement Notice and shall continue until [Date] / [all shares are sold]. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE PARTIES</B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Plus Therapeutics, Inc.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Andrew Sims </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">asims@plustherapeutics.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kara Davis </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">kdavis@plustherapeutics.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Canaccord Genuity LLC </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian O&#146;Connor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">boconnor@cgf.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Wright </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">mwright@cgf.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jennifer Pardi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jpardi@cgf.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AND </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CGUSEcm@cgf.com </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF REPRESENTATION CERTIFICATE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 3(Q) OF THE AGREEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Date] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CANACCORD GENUITY LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">99 High Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02110 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Sirs: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, the duly qualified
and elected chief executive officer and chief financial (or chief accounting) officer, of Plus Therapeutics, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), do hereby certify in such capacities and on behalf of the Company, pursuant
to <U>Section</U><U></U><U>&nbsp;3(q)</U> of the Equity Distribution Agreement, dated September&nbsp;9, 2022 (the &#147;<B>Equity Distribution Agreement</B>&#148;), by and between the Company and Canaccord Genuity LLC, that to the best of their
knowledge: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The representations and warranties of the Company in Section&nbsp;1 of the Equity Distribution
Agreement (A)&nbsp;to the extent such representations and warranties are subject to qualifications and exceptions contained therein relating to materiality or Material Adverse Effect, are true and correct on and as of the date hereof with the same
force and effect as if expressly made on and as of the date hereof, except for those representations and warranties that speak solely as of a specific date and which were true and correct as of such date, and (B)&nbsp;to the extent such
representations and warranties are not subject to any qualifications or exceptions, are true and correct in all material respects as of the date hereof as if made on and as of the date hereof with the same force and effect as if expressly made on
and as of the date hereof except for those representations and warranties that speak solely as of a specific date and which were true and correct as of such date; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied
pursuant to the Equity Distribution Agreement at or prior to the date hereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms used herein without definition shall have the meanings given to such terms
in the Equity Distribution Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief&nbsp;Executive&nbsp;Officer </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUBSIDIARIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d359404dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">


<IMG SRC="g359404img.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hogan Lovells US LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">609 Main Street,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 4200</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Houston, TX 77002</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T +1 713 632 1400</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">F +1 713 632 1401</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">www.hoganlovells.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;9, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Board
of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Plus Therapeutics </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4200 Marathon Blvd., Suite
200 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Austin, TX 78756 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the addressee referred to above:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are acting as counsel to Plus Therapeutics, a Delaware corporation (the &#147;<B>Company</B>&#148;), in connection with its registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> (No. <FONT STYLE="white-space:nowrap">333-249410),</FONT> as amended (the &#147;<B>Registration Statement</B>&#148;), filed with the Securities and Exchange Commission under the Securities Act of 1933,
as amended (the &#147;<B>Act</B>&#148;) relating to the proposed public offering of up to $5,000,000 of the Company&#146;s common stock, par value $0.001 per share (the &#147;<B>Shares</B>&#148;), to be sold by the Company from time to time and at
various prices in an &#147;at the market offering&#148; pursuant to the Equity Distribution Agreement, dated September&nbsp;9, 2022 (the &#147;<B>Agreement</B>&#148;), between the Company and Canaccord Genuity LLC, as sales agent (the
&#147;<B>Agent</B>&#148;). This opinion letter is furnished to you at your request to enable you to fulfill the requirements of Item&nbsp;601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> 17&nbsp;C.F.R. &#167;&nbsp;229.601(b)(5),
in connection with the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this opinion letter, we have examined copies of such agreements, instruments and documents
as we have deemed an appropriate basis on which to render the opinions hereinafter expressed. In our examination of the aforesaid documents, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the accuracy
and completeness of all documents submitted to us, the authenticity of all original documents, and the conformity to authentic original documents of all documents submitted to us as copies (including pdfs). As to all matters of fact, we have relied
on the representations and statements of fact made in the documents so reviewed, and we have not independently established the facts so relied on. This opinion letter is given, and all statements herein are made, in the context of the foregoing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion letter is based as to matters of law solely on the applicable provisions of the Delaware General Corporation Law, as amended and as
currently in effect. We express no opinion herein as to any other statutes, rules or regulations (and in particular, we express no opinion as to any effect that such other statutes, rules or regulations may have on the opinion expressed herein).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this opinion letter, we have assumed that the terms of the sale of the Shares to be sold pursuant to the Agreement will have been duly
authorized and established by proper action of the Board of Directors of the Company (the &#147;<B>Board</B>&#148;) or a duly authorized committee of the Board (&#147;<B>Board Action</B>&#148;) consistent with the requirements of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon, subject to and limited by the foregoing, we are of the opinion that following (i)&nbsp;execution and delivery by the Company and the Agent of the
Agreement, (ii)&nbsp;effectiveness of the Registration Statement, (iii)&nbsp;issuance of the Shares pursuant to the terms of the Agreement and in accordance with the Board Action, and (iv)&nbsp;receipt by the Company of the consideration for the
Shares specified in the Board Action, the Shares will be validly issued, fully paid, and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Hogan Lovells US LLP is a limited liability
partnership registered in the District of Columbia. &#147;Hogan Lovells&#148; is an international legal practice that includes Hogan Lovells US LLP and Hogan Lovells International LLP, with offices in: Alicante Amsterdam Baltimore Beijing Birmingham
Boston Brussels Colorado Springs Denver Dubai Dusseldorf Frankfurt Hamburg Hanoi Ho Chi Minh City Hong Kong Houston Johannesburg London Los Angeles Luxembourg Madrid Mexico City Miami Milan Minneapolis Monterrey Munich New York Northern Virginia
Paris Perth Philadelphia Rome San Francisco S&atilde;o Paulo Shanghai Silicon Valley Singapore Sydney Tokyo Warsaw Washington, D.C. Associated Offices: Budapest Jakarta Riyadh Shanghai FTZ Ulaanbaatar. Business Service Centers: Johannesburg
Louisville. Legal Services Center: Berlin. For more information see www.hoganlovells.com </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Canaccord Genuity LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">- 2 -</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">September 9, 2022</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion letter has been prepared for use in connection with the Registration Statement. We assume no
obligation to advise of any changes in the foregoing subsequent to the effective date of the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of
this opinion letter as Exhibit 5.1 to the Registration Statement and to the reference to this firm under the caption &#147;Legal Matters&#148; in the prospectus supplement constituting a part of the Registration Statement. In giving this consent, we
do not thereby admit that we are an &#147;expert&#148; within the meaning of the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Hogan Lovells US LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HOGAN LOVELLS US LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>pstv-20220909.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 9/10/2022 12:13:07 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:pstv="http://www.plustherapeutics.com/20220909"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.plustherapeutics.com/20220909"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pstv-20220909_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pstv-20220909_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>pstv-20220909_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 9/10/2022 12:13:07 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>pstv-20220909_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 9/10/2022 12:13:08 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="pstv-20220909.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g359404img.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g359404img.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M^ 'L_,/^$J_Z<O\ R+_]:C_67_IU_P"3?\ /9^8?\)5_TY?^1?\ ZU'^LO\
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ME_A7Y(Y9;LYSQ/\ \A*/_KD/YFOD.(_]ZC_A7YLVI[&+7SIH% !0 4 % !0
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(."A'9:(@_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140104508886144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001095981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  09,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PLUS THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0827593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4200 Marathon Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(737)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-7194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PSTV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>d359404d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pstv-20220909.xsd" xlink:type="simple"/>
    <context id="duration_2022-09-09_to_2022-09-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <startDate>2022-09-09</startDate>
            <endDate>2022-09-09</endDate>
        </period>
    </context>
    <dei:SecurityExchangeName
      contextRef="duration_2022-09-09_to_2022-09-09"
      id="Hidden_dei_SecurityExchangeName">NASDAQ</dei:SecurityExchangeName>
    <dei:AmendmentFlag contextRef="duration_2022-09-09_to_2022-09-09">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-09-09_to_2022-09-09"
      id="Hidden_dei_EntityCentralIndexKey">0001095981</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-09-09_to_2022-09-09">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-09-09_to_2022-09-09">2022-09-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2022-09-09_to_2022-09-09">PLUS THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-09-09_to_2022-09-09">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-09-09_to_2022-09-09">001-34375</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-09-09_to_2022-09-09">33-0827593</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-09-09_to_2022-09-09">4200 Marathon Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2022-09-09_to_2022-09-09">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-09-09_to_2022-09-09">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-09-09_to_2022-09-09">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-09-09_to_2022-09-09">78756</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-09-09_to_2022-09-09">(737)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-09-09_to_2022-09-09">255-7194</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-09-09_to_2022-09-09">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-09-09_to_2022-09-09">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-09-09_to_2022-09-09">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-09-09_to_2022-09-09">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-09-09_to_2022-09-09">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-09-09_to_2022-09-09">PSTV</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-09-09_to_2022-09-09">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MW7X-(F:&>8\B@M<KDE))=C3*&/G@W$"=QS@KS_=PDUY*&II\6[S%*U&?;;B
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M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( &&%*57A@( P[0   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( &&%
M*5697)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ 884I50_%DMID!   *!$  !@
M ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( &&%
M*56?H!OPL0(  .(,   -              "  :8,  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ 884I59>*NQS     $P(   L              ( !@@\
M %]R96QS+RYR96QS4$L! A0#%     @ 884I51PX9>H_ 0  / (   \
M         ( !:Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( &&%*54D
M'INBK0   /@!   :              "  =<1  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( &&%*55ED'F2&0$  ,\#   3
M      "  ;P2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
'  84      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d359404d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName -  d359404d8k.htm 7</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="d359404d8k.htm">d359404d8k.htm</File>
    <File>d359404dex11.htm</File>
    <File>d359404dex51.htm</File>
    <File>pstv-20220909.xsd</File>
    <File>pstv-20220909_lab.xml</File>
    <File>pstv-20220909_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d359404d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d359404d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pstv-20220909_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pstv-20220909_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pstv-20220909.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "pstv",
   "nsuri": "http://www.plustherapeutics.com/20220909",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d359404d8k.htm",
      "contextRef": "duration_2022-09-09_to_2022-09-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d359404d8k.htm",
      "contextRef": "duration_2022-09-09_to_2022-09-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-22-242028-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-242028-xbrl.zip
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MZ"( 8_K5*(8U2RP0+(7\T^=6([[E)\&F_I7SDY^2 Y#$/L<.CM84<C]IR><
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M!_]!PT29*-LZJR_I/[*BS!?R4QXT+%N+IPD_@U^0W,(?LA97>;,JLA+&A"_
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M[S&T=?=':.OS76/C$/YG.!.TR@Q>Y!&GZWPX:CK9"V*PS@JN.2STH09A+3E
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MTR(DU7)EI8,^H\BKR +;46QE2^NQ?58IN=(B/3+QU/ZS:2_K'9>%  %VBL_
MFQR)AC86''];:)DO,/!,1Y@U%H9P2Z.RR&@@DTY.#$JA8Z[\6 'Y*/F@ 8NG
MU\QA,<A<N]+1N-JF/_YT)^-*$^\D3D8Q_Z):FDBOY$W@.(B"(7OM<DB$-5[
MSP C%:X57QG&HV-9Z(OR[ CR8/8?_"#V5Y&XNZ5P>2L-VAD@BBO1NV>@U/;:
M-,I_/ EU=*18W'XAY[N/K%RI$H*5#DXK1U2S=-7IE@:0KRG_S6]:2PZ%JO%
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M7JOL(DUD/:B?]N"")&8]\(F<#AA8F&![^@>&GDBV:JKP&70+=#@<]E_0@="
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M?T_^S$OJ,R=<[-S@) 2.5)'=T"9W;AT=P9/K#*Z!,GFX.E_<!"-Q"_HY@;_
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M+C57HX)\(V,Y%^);6G9B2.J/6PSKJJ @Z/21:P#T9*IW!X<= J-+Y *U4JS
M)C;J3KX>F!&<,Q"(<PW+QNA3#,0)W:+*"YX3@NWI9(^"NSRDO<%0E6>>NFTQ
M?=>R,'90&8:<(ZT?X BLLQBC7'0EF4(EQV6F15_LZ_+@/=>N#8LQ:XE8_$*@
MC>B!L .3O&_Y>E9T<!7YA26Z)-8"'@1 0J& 7##2"3"' /U/6C+9P*AIH@-_
M&$% QHY1) $Z#^X7*J*FN*M6:QE0/?$>@RL"&UNQQ:1@!N;DFMIL,T#;<_@\
MR#VN"JQ855"%8%C\VQ(*W !J)0(S>B80V&YQ3IB=$E?-PE</27^,N HSG!L
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MXPJQ_)&L<X5F/F-I]&7I_8@@ F8^';F \SR_EP"!F5"I_Q*WNQ]%J%05-4M
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MLF2:^LQI\"I7_.)9=.Z6_@=02P,$%     @ 884I545=('%]"P  I"0  !
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MB0*M%O6.T$9JQ*83X\\=#SWEJ!]@ M,V,/C8K2'8Z&.PL_B*,(X[BS5Y"U\
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M'U!+ 0(4 Q0    ( &&%*55.MH?J7Q,   5S   .              "  0
M  !D,S4Y-# T9#AK+FAT;5!+ 0(4 Q0    ( &&%*55"AGR,Z8<   6@ @ 0
M              "  8L3  !D,S4Y-# T9&5X,3$N:'1M4$L! A0#%     @
M884I545=('%]"P  I"0  !               ( !HIL  &0S-3DT,#1D97@U
M,2YH=&U02P$"% ,4    " !AA2E53Z-<@TD#  !L"P  $0
M@ %-IP  <'-T=BTR,#(R,#DP.2YX<V102P$"% ,4    " !AA2E5>JSN5G\&
M  "[1@  %0              @ '%J@  <'-T=BTR,#(R,#DP.5]L86(N>&UL
M4$L! A0#%     @ 884I5</).5S-!   42P  !4              ( !=[$
L '!S='8M,C R,C Y,#E?<')E+GAM;%!+!08     !@ & 'T!  !WM@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
